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VII SUMMARY
Although renal cell carcinoma accounts for only 2% of all cancers it is responsible 
for 12% of all cancer deaths making it a particularly lethal malignancy. Over the last 50 
years there has been an increased incidence in all stages of disease with the greatest rise 
observed in localised lesions found incidentally due to increased used of radiological 
imaging.
The mainstay of treatment for the 60% of patients presenting with only localised 
disease is surgery however, despite aggressive surgical management 30% of patients 
with no evidence of métastasés at the time of surgery will subsequently develop 
métastasés. The median survival of patients either presenting or developing metastatic 
disease is 8.5 months even in those who are suitable for immunotherapy.
Currently staging and consequently the prognosis of patients with renal cancer is 
based on macroscopic tumour characteristics and the presence or absence of lymph node 
and distant métastasés as defined by the American Joint Committee on Cancer TNM 
staging system. Stage alone has been shown to be inadequate in predicting outcome and 
combination with grade and histological subtype has been shown to improve 
prognostieation in patients with renal cancer.
Additionally patient factors are thought to contribute to patients overall cancer 
specific suiwival including the presence of cachexia and poor performance status. The 
reasons for these factors influencing survival are not clear but their potential 
relationship with the systemie inflammatory response, as evidenced by raised 
circulating concentrations of C-reactive protein is thought to be significant.
Previous work has shown that elevated C-reactive protein signifying a systemic 
inflammatory response is of independent prognostic value in patients undergoing 
potentially curative resection for a variety of common solid tumours.
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In chapter 2 we examined patients undergoing potentially curative nephrectomy 
for renal cancer, the presenee of a systemic inflammatory response has been tested for 
its prognostic significance against the UISS (UCLA Integrated Staging System) an 
internationally validated prognostic algorithm incorporating stage, grade and 
performance status.
In this study of 100 patients a raised C-reactive protein was found to be an 
independent prognostic factor for cancer specific survival on both univai’iate and 
multivariate analysis. Furthermore inclusion into the UISS allowed better stratification 
of patients defined by this algorithm as low or intermediate risk of progression.
Previous studies have suggested that the local inflammatory response as defined 
by the presence of a pronounced lymphocytic infiltration, in particular tumour CD4+ 
and CD8+ T-lymphocytes, ai*e associated with poorer cancer specific survival in renal 
cancer. How this local response relates to the systemic response in renal cancer has not 
been previously examined.
It was of interest how these effectors of immune function related to the mediators 
of inflammation within the tumour micro-environment. Cyclo-oxygenase-2 is the 
enzyme responsible for the production of prostaglandins the prime mediators of 
inflammation and where over-expressed has been implicated with poor outcome in a 
number of common solid tumours. Cyclo-oxygenase-2 has been reported to stimulate 
production of interleukin-6 a potent pro-inflammatoiy cytokine which acting through its 
receptor has been linked with tumour genesis and progression in renal cancer. Few 
studies have examined the expression of cyclo-oxygenase-2 in renal tumours.
In chapter 3 patients undergoing nephrectomy for renal cancer were examined for 
CD4+ and CD8+ tumour lymphocytic infiltrate, interleukin-6 receptor expression, 
cyclo-oxygenase-2 expression as well as coneentrations of cireulating C-reactive protein
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with relation to cancer specific survival. Both elevated C-reactive protein and increased 
numbers of CD4+ lymphocytic infiltrate were associated with poorer cancer specific 
survival. A positive relationship was also demonstrated between T-lymphocytic 
infiltrate and C-reactive protein and were both significantly associated with increased 
grade of tumoui* suggesting an association with more aggressive tumour biology. 
Cyclo-oxygenase-2 and interleukin-6 receptor expression were found to be independent 
of tumour stage, grade, lymphocytic infiltrate and not related to eancer specific sui'vival.
In conclusion the work presented in this thesis suggests that both the presence of a 
systemic or a local inflammatory response are negative prognostic factors in patients 
undergoing nephrectomy for renal cancer. Systemic C-reactive protein and tumour 
lymphocytic infiltrate are significantly associated with each other. Tumoui* expression 
of cyclo-oxygenase-2 and interleukin-6 receptor are independent of circulating C- 
reactive protein and local lymphocytic infiltrate and are therefore the basis for the link 
between the loeal and systemic inflammation observed in renal cancer is unclear and 
warrants further study.
15
Chapter 1
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1.0 INTRODUCTION
1.1 Incidence and Mortality of Renal Cancer
Malignant tumoui's of the kidney account for around 2% of all new cancer cases 
and deaths in North America (Landis et al.  ^ 1998). Internationally the overall ineidence 
of RCC has been seen to be increasing at a greater rate relative to other cancers (Reis et 
aL, 1998). Renal cancer has demonstrated increased incidence in all age groups over 
the past 50 years, with the greatest rise observed in loealised tumours (Chow et aL, 
1999). All stages including localised, regional and distant have shown an increase as 
well as an increase in renal carcinoma mortality rates (Hock et aL, 2002). The reason 
for this increased incidence is unclear. For example in North America the increase in 
incidence of renal cancer has been noted to be more rapid in the black population 
relative to whites. Black men have shown an increase rate of 3.9% and black women by 
4.3% per year, compaied with 2.3% for white men and 3.1% for white women (Chow et 
aL, 1999). As a result the black population now have a higher incidence rate than the 
white population (Kosary et aL, 1993),
In Scotland cancer of the kidney accounts for 2.7% of all cancers in males (324 
new cases/ year) and 1.8% of all cancers in females (217 new cases/ year) (Scottish 
Flealth Statistics, 2000).
Renal cell carcinoma is predominantly a disease of the elderly with a median age 
of diagnosis of 65 (Vogelzang et aL, 1998). Men are approximately twice as likely to 
develop RCC as women, with in Scotland, a median age of 67 in men and 69 in women. 
The Scottish figui'es show a male to female ratio of 3:2.
At the time of presentation approximately one third of patients will have 
metastatic disease. Of patients who undergo radical surgery with curative intent 30-
17
50% will ultimately develop distant métastasés (Flannigan and Yonover, 1996). 
Therefore over the course of their disease, approximately 60% of all patients with renal 
cancer will progress to metastatic disease, which carries a very poor prognosis with 
median survival of approximately 8 months (DeKiemon et aL, 1978).
The pattern of presentation has altered over the past two decades with the 
amount of lesions diagnosed incidentally increasing due to the rise in use of ultrasound 
scanning, computerised tomography (CT) and magnetic resonance imaging (MRI). 
However this increased detection of asymptomatic lesions due to higher levels of 
imaging does not fully explain the rise in incidence of renal cancer.
In their study of 9 cancer registries Hock and co-workers (2002) concluded that 
there was no difference in stage at presentation of renal carcinoma diagnosed 1973-85 
compared to 1986-98. Increased incidence in all 3 stages; localised, regional and distant 
were noted over this time period. Significant reduction in distant disease has not been 
observed despite the increased detection of localised and regional tumours through 
incidental findings on imaging. Indeed a more contemporary study has confirmed 39% 
patients continue to present with metastatic disease (Leslie et al. 2003)
This would suggest that many such incidentally diagnosed masses are slow 
growing, and of uncertain malignant behaviour. This is consistent with the fact that the 
rise of incidentally diagnosed renal carcinoma treated by nephrectomy has not 
significantly altered the overall mortality rate for RCC (Chow et aL, 1999; Rendon et 
aL, 2000). Leslie and co-workers observed a significant difference in 5 year disease 
specific survival between incidental lesions and symptomatic lesions at diagnosis of 94 
and 35% respectively treated by nephrectomy. This survival difference may represent 
tumours detected before they would ultimately become symptomatic and follow a more 
aggressive course or alternatively are inlierently less likely to progress.
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In summary, over the past two decades the method of presentation of the 
majority or renal cancers has seen a shift toward incidentally detected lesion, without 
any evidence to suggest an overall improvement in survival. This would indicate that a 
number of tumour's continue to behave in an inherently aggressive mamier, whilst others 
follow a more indolent course. Identifying those tumours which will behave in a more 
aggressive manner remains of utmost priority if we are to improve outcome.
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1.2 Aetiology of Renal Cell Cancer
The precise aetiology of renal cancer is unknown, however sporadic RCC 
accounts for approximately 90% of all cases. A number of risk factors for the 
development of renal cancer have been identified.
1.2.1 Genetics of Renal Cancer
The most well characterised familial syndrome associated with renal cancer is 
the von Hippel-Lindau syndrome (VHL). This syndrome is associated with highly 
vascular tumours of multiple organs including the central nervous system, kidney, 
adrenal and pancreas (Lamiell et aL, 1989). VHL syndrome inlrerited in an autosomal 
dominant manner, occurs in 1: 40,000 live births and is associated with a 70% 
probability of developing RCC by the seventh decade (Maher and Kaelin, 2001). The 
syndrome was first described by Cushing and Bailey (Cushing and Bailey 1926), with 
the VHL defect ultimately identified and isolated to the VHL tumour suppressor gene 
3p 25-26 in 1993 (Latifer aL, 1993).
In these patients renal cancer presents earlier in life than in sporadic tumours 
with a mean age of 35 years. The histology is of clear cell carcinoma and is present as 
multiple microscopic tumoui' foci which can grow and develop. For example a 37 year 
old patient with VHL may have more than 600 independent solid tumours and 1100 
cysts (Walther et aL, 1995) Figm'el.l.
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Figure 1.1 A computerised tomography image of patient with Von-Hippel 
Lindau disease demonstrating bilateral multiple renal cysts with three solid 
tumours (arrowed) (Tao L., www.cortlandtforum.com).
For tumoiu's to develop both alleles for the VHL suppressor gene must be lost. 
Patients with VHL are bom with a germline mutation at one VHL locus. As only a 
single further mutation is required of the opposite allele the chances of tumour 
formation in these patients is substantially increased (Maranchie and Linehan, 2003). 
Such a mutation may arise by loss of heterozygosity, mutation of the second allele itself 
or thi’ough silencing of the VHL promoter by DNA hypermethylation (Prowse et al., 
1997).
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There is also a high frequency of VHL alteration identified in sporadic RCC; 50- 
65% of sporadic cleai* cell carcinomas are found to have VHL mutations of which 85% 
are through loss of heterozygosity at the VHL locus (Gnana et aL, 1996). Such 
mutations do not arise in the other histological types of RCC, namely papillary or 
chromophobe tumours.
Genetic factors observed in other histological variant familial cases are not 
commonly observed in respective sporadic cases. Hereditary papillary renal carcinoma 
demonstrates MET gene mutations on chromosome 7 which are not found in the 
majority of sporadic papillary tumours suggesting an alternate pathway in the 
development of these more common lesions (Linehan et aL, 2003). Familial 
chromophobe renal cancer is associated with Birt-Hogg-Dube. The Birt-Hogg-Dube 
gene normally functions as a tumoui’ suppressor gene (Nickerson et aL, 2002). It is yet 
to be determined whether such mutations occur in sporadic forms of chr omophobe renal 
cell car cinoma.
1.2.2 Hvpoxia Inducible Factor role in sporadic RCC
VHL is thought to act predominantly to regulate cell cycle arrest and the 
transition to quiescence under conditions in which cells transit to GO (Pause et aL, 
1997). It does this by changing the stability of p27. It has also been noted that loss of 
VHL function correlates with an increase in expression of vascular endothelial growth 
factor which is over expressed in well vascularised tumours such as renal cell cancer 
(Siemeister et aL, 1996).
Glucose transporter-1 and transforming grovrth factor a  along with vascular 
endothelial growth factor are hypoxia induced genes (Gnarra et aL, 1996; Iliopoulos et 
aL, 1996). The expression of these genes is controlled by hypoxia-inducible
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transcription factors. These factors are activated in response to reduced cellular oxygen 
tension and mediate their effects through hypoxia response elements to increase 
transcription of hypoxia induced genes. Hypoxia inducible factors are heterodimers 
comprised of a hypoxia inducible factor a  subunit and the aryl hydrocarbon nuclear 
translator (Semenza et ah, 2000). Hypoxia inducible factor a  subunits are continually 
synthesised but rapidly ubiquitinylated and broken down by proteosomal degradation in 
normoxic conditions. VHL protein functions as the substrate recognition subunit of a 
multiprotein E3 ubiquitin ligase (Patton et ah, 1998). Where VHL is mutated or absent 
hypoxia inducible factor a  subunits are not able to be ubiquitinylated resulting in 
increased expression of hypoxia inducible genes which are thought to be responsible 
both for the development and propagation of renal tumoui’s.
1.2.3 Risk factors for renal cancer
Hypertension
There is an extensive literature on the association between hypertension and 
renal cancer. However, difficulty arises in separating hypertension from other 
confounding variables. Two studies adjusted for age, tobacco smoking and Body Mass 
Index but not antihypertensives have demonstrated an association between hypertension 
and renal cancer (Mellemgaard et ah, 1994; Schlehofer et ah, 1996). In one of the 
largest studies, carried out in Sweden, a direct and significant relationship was observed 
between elevated systolic and diastolic pressure (Chow et ah, 2000). Diastolic pressure 
of 90 mm Hg or more had twice the incidence of renal cancer than those men with 
diastolic less than 70 mm Hg. A systolic blood pressui'e greater than 150 mm Hg was 
associated with a 60 -  70% higher risk than those with a pressure below 120 mm Hg.
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There was also a decrease in renal cancer risk with a decrease in blood pressure over 
time.
The proposed mechanism for hypertension increasing the risk of renal cell 
carcinoma is related to the changes observed in renal parenchyma secondary to 
development of hypertension. Hypertensive nephropathy may result in the kidney 
becoming more sensitive to carcinogens. Alternatively the increase in angiogenic and 
other growth factors seen with hypertension may be responsible for this association with 
the development of renal cancer (Schena et ah, 1999).
Obesity
Obesity has been consistently shown to be associated with renal cell carcinoma, 
particularly among women (McLaughlin et al., 1984; Mellemgaard et ah, 1995). The 
association is observed only in the severely obese who have a Body Mass Index above 
the fourth quartile. Mellemgaard and co-workers (1995) reported that weight cycling or 
large swings in weight appeared to play a significant role in the development of renal 
cancer. However, the age at which obesity develops does not influence this association. 
The mechanism for the effect of obesity on renal cancer is unclear. Although studies 
are often not adjusted for hypertension, which in many instances accompanies obesity, 
there is broad agreement among a large number of studies that classify obesity as a risk 
factor for renal cancer. Scotland has rising levels of obesity.
Tobacco
A dose-response association has been demonstrated in relation to cigarette 
consumption and development of renal cell carcinoma (Chow et at., 2000). Heavy 
smoking increases the risk of renal cancer by 2 ~ 2.5 times that of non smokers (Yuan et
24
ah, 1998). Smoking in men appears to result in a higher incidence of renal cancer (20- 
30%) relative to the increase in smoking women (10-20%) (Yuan et al., 1998).
In summaiy while genetic defects are common, particular at the VHL locus in 
approximately 75% of sporadic tumours, the causes of these genetic mutations which 
precipitate this chain of events are largely unknown but a number of risk factors have 
been described. It should be noted that the principle risk factors for renal cancer are 
also those for cardiovascular disease. In addressing these risk factors consideration 
must be taken into the relative rare incidence of renal cell carcinoma. These risk factors 
should be tackled on the basis of their caidio protective basis rather than any relative 
weak association with renal cancer. The presence of these risk factors may in time 
allow a rationale for targeted screening in the futuie along with abdominal aortic 
aneurysm, a condition with similar associations.
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1.3 Pathology of Renal Cancer
1.3.1 Momholosv
Renal tumours may arise from any portion of the kidney, but more commonly 
arises from one of the poles (Robbins et al., 1989). Lesions are usually solitary and 
unilateral and are spherical in shape. The cut surface is often haemorrhagic and may 
appear bright yellow due to the high lipid content of these tumours. Areas of ischaemic, 
opaque, gray/ white necrosis are commonly observed.
Renal tumours are expansile in nature often compressing adjacent renal 
parenchyma into a pseudocapsule (McGee et al., 1992). As they enlarge they may 
protrude into the calyces, eventually fungating thi'ough the wall of the collecting system 
and even into the ureter. Often where the collecting system is involved patients will 
experience frank haematuria.
1.3.2 Histogenesis
Renal cell carcinoma is thought to arise from renal tubules. The presence of a 
readily demonstrable brush border found on ultrastructuial analysis suggests the origin 
to be from the proximal tubular epithelium (McGee et al., 1992). The cellular origins of 
renal cancer have been further studied using immuno-histochemistry techniques 
utilising monoclonal antibodies specific to antigens of different tubular cells. Most 
renal cell carcinomas express antigens from the proximal tubular epithelium, but many 
express antigens of the distal tubule and both antigens may coexist in the same tumour. 
This may be explained by aberrant differentiation of renal tumour cells along with the 
possible origins of tumours from various parts of the nephron.
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1.3,3 Histology
The classification of renal cell neoplasms derived from renal epithelial cells
follows a standardised nomenclature summarised below Table 1.1 (Storkel et ah, 1997).
Table 1.1 Classification of renal tumours.
Classification of renal tumours Proportion
Malignant Clear cell/ conventional 70-80%
Papillary 7-15%
Chromophobe -5%
Collecting Duct 1%
Unclassified 1%
Benign Adenoma <1%
Oncocytoma '5%
Metanephric Adenoma <1%
Clear Cell/ Conventional Renal Cell Carcinoma
Clear cell carcinoma represents the commonest cell type found in neoplasms of 
the kidney. These account for 70-80% o f renal cancers. The name clear cell is derived 
from the histological appearance. These cells have an abundant apparently empty 
cytoplasm due to the high lipid content, which is removed during processing for 
embedding in paraffin wax. The cytoplasm contains vacuoles which are usually 
peripheral with the rest o f the cytoplasm centrally placed. They also contain glycogen 
Figure 1.2. Some cells are found to have a more granular cytoplasm, hence the move to 
rename these as conventional rather than clear cell type.
Figure 1.2 A H&E histological slide of a clear cell carcinoma of kidney 
(webpathology.com).
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Clear cells may be round or polygonal in shape and tend to be airanged in a 
tubular or acinar pattern. Some may display papillary features particularly when within 
cysts (McGee et ah, 1992). The cells are usually supported by a rich sinusoidal vascular 
architecture. High grade variants show loss of this cytology and architectural pattern. 
The nucleus has a typical prominent nucleolus and may be eccentric to the cell, and may 
even appear paitially extruded (Renshaw et al., 2000). Higher grade tumours have more 
isolated cells and less cytoplasmic vacuolisation. Tumours tend to have a fibrous 
pseudocapsule but the presence of a less well defined infiltiative margin is an ominous 
feature and suggests sarcomatoid transformation (Fleming and O’Donnell, 2000). 
Approximately 10-15% of these tumours will be cystic or pseudocystic as a 
consequence of tumour necrosis and haemorrhage (Eble and Bosnib, 1998).
The most useful immunohistochemical markers to define clear cell carcinoma 
are cytokeratin, vimentin and EMA (Fleming and Symes, 1987; Rahilly et ah, 1992; 
Fleming et ah, 1985). In most cases diagnosis is straightfoi*ward but metastatic tumours 
can be more difficult to diagnose due to cells becoming very “bland”. 
Immunohistochemistry has particular use in such cases.
29
Papillary Renal Carcinoma
For tumours to be defined as papillary at least 50% true papillae must be 
observed (Renshaw and Corless, 1995). Papillary tumours represent 7-15% o f all renal 
cell carcinomas. The gross appearance has characteristic flecks o f  gold in a background 
o f haemorrhage (Renshaw and Corless, 1997). The cells lining the papillae are either 
cuboidal or columnar type Figure 1.3. Studies have suggested that the cellular subtype 
defines prognosis with cuboidal (Type 1) having a better outcome than papillary (Type 
2) (Delahunt and Eble, 1997). Cells are either basophilic with scant cytoplasm or 
eosinophilic with abundant granular cytoplasm. Papillae may be recognisable or may 
appear as spherules or tubules. Often fibrovascular cores distended with macrophages 
are seen (Weir and Pitman, 1996).
Figure 1.3 A H&E histological slide of a papillary carcinoma of kidney 
(webpathology.com).
Papillary carcinoma is usually accompanied by the presence o f papillary 
adenomas in the cortex. It is the type o f  renal carcinoma which complicates renal cystic 
disease most frequently in the dialysis population (Ishikawa and Kovacs, 1993).
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Papillary tumours like clear cell show cytokeratin and EMA reactivity but are 
less likely to be vimentin positive. They are also positive for cytokeratin 7 which may 
prove to be a useful diagnostic marker (Renshaw and Corless, 1995).
Chromophobe Carcinoma
Five percent o f all renal cell carcinomas are chromophobe tumours which carry 
a better prognosis unless large or multifocal (Renshaw et al., 1996). On gross 
inspection these tumours are uniformly soft and grey, and can occasionally have central 
stellate scarring to mimic oncocytoma. Tumour cells show weak uptake o f eosin 
staining hence their name, with pale staining membrane bound vesicles and perinuclear 
halo formation (Thoenes et al., 1985) Figure 1.4.
Figure 1.4 A H&E histological slide of a chromophobe carcinoma of kidney 
(webpathology.com).
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Collecting Duct Carcinoma
Only 1% or renal cancers are collecting duct tumours, but these behave in a 
highly aggressive manner, affecting a younger age group with 90% o f those diagnosed 
succumbing to their disease (Fleming and Lewi, 1986). It demonstrates tubulopapillary 
histology with high-grade cytology and prominent desmoplasia (Baer et al., 1993) 
Figure 1.5.
......
Figure 1.5 A H&E histological slide of a collecting duct carcinoma of kidney 
(webpathology.com).
Unclassifiable Renal Malignancy
As the name suggests there are a number o f tumours in which the original 
epitheliod element cannot be identified and classified. These tumours tend to have 
mixtures o f components, unrecognizable architecture or sarcomatoid pattern (Fleming 
and O’Donnell, 2000).
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Oncocytoma
This represents the commonest benign lesion of the kidney and accounts for 5% 
of all surgically resected renal masses. They are well circumscribed, tan coloured 
tumours with a central stellate sear (Fleming and O’Donnell, 2000), Vascular* channels 
are present at the margins of the lesion which giyes a classic cartwheel appeai*ance on 
angiography (Lieber et a l, 1981). Histologically it appears as nests and sheets of 
intensely granular eosinophillic cells. The nests are found in a mucopolysaccharide rich 
extracellular matrix (Amen et al., 1997). They show minimal nuclear* pleomorphism 
except in ischaemic areas and mitotic actiyity is rare.
Renal Cortical Adenoma
These are benign lesions that ar*e histologically, immunohistochemically and 
cytogenetically indistinguishable from low grade papillary renal cell carcinomas except 
by size (Grignon and Eble, 1998), They are defined by size and are always less than 
5mm and usually less than 2mm and are identified incidentally in 4-37% of kidneys at 
autopsy (Xipell, 1971).
Metanephric Adenoma
These are benign lesions most commonly arising in women in the 5^  ^ decade 
(Strong and Ro, 1996). They are characterised by a well circumscribed margin, white 
appearance and are usually firm although larger lesions are softer. Tumours are 
composed of tubules and papillae forming “glomeruloid bodies” lined by uniformly 
bland cells, with occasional psammoma bodies (Renshaw et al., 2000).
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1.3.4 Grade
Histological grade has been identified as an independent factor of prognosis in 
many studies (Medeiros et ah, 1988; Hofmockel et ah, 1995; Bretheau et ah, 1995). 
The most commonly used system for grading renal tumours is that proposed by 
Fuhrman (Fuhrman et ah, 1982). This study examined 103 patients undergoing 
nephrectomy between 1961 and 1974. Four nuclear grades were defined in order of 
increasing nuclear size, irregularity and nucleolar' prominence shown below (Table 1.2).
Table 1.2 Fuhrman grading system for renal cell carcinoma.
Fuhrman
Grade
Histological features Malignant
Potential*
Grade 1 Small (approx. lOp) round uniform nuclei with 
inconspicuous or absent nucleoli.
9%
Grade 2 Larger (approx. 15p) nuclei which exhibited irregularities 
in outline and nucleoli under high x400 power.
61%
Grade 3 Large (approx. 20p) nuclei with an obviously irregulai' 
outline and prominent nucleoli even at low xlOO power.
79%
Grade 4 Similar features to G3 with additional bizane, often 
multilobed nuclei and heavy chromatin clumps.
67%
^Denotes the percentage of patients developing métastasés independent of stage 
according to Fuhrman’s original series over 5 year follow up.
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Sarcomatoid Differentiation
Sarcomatoid change is recognised as a progression factor with loss o f epithelial 
phenotype rather than a distinct tumour type. It is characterised by a spindle cell 
histologic appearance with ultrastructural or immunohistochemical evidence o f  
epithelial and mesenchymal differentiation. Sarcomatoid change has been reported in 
all distinct histological subtypes o f renal cancers (de Peralta-Venturina et al., 2001).
It occurs in approximately 8% o f  renal tumours and can be associated with any 
histological subtype, grade or stage o f  tumour. Sarcomatoid change confers an adverse 
prognosis. This is more pronounced when the percentage o f sarcomatoid component 
exceeds 50% (de Peralta-Venturina et al., 2001).
i W
Figure 1.6 A H&E histological slide of a sarcomatoid carcinoma of kidney 
(webpathology.com).
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1.4 Clinical Features of Renal Cell Carcinoma
The classical triad of symptoms of haematuria, loin pain and an abdominal mass 
are rarely all present in patients with newly diagnosed renal cancer. More commonly 
patients present with one or no symptoms to suggest a diagnosis of renal cell carcinoma. 
Kim and co-workers (2003) examined 1046 patients with localised and metastatic renal 
cancer and found that haematuria was present in 35.2% of cases, loin pain 19.5% and an 
abdominal mass 4.4%of patients. Localised to metastatic ratios for haematuria, loin 
pain and abdominal masses are respectively 0.8, 0.6 and 0.4 demonstrating patients with 
metastatic disease are more likely to present symptomatically. Patients with metastatic 
disease and have a higher incidence of all paraneoplastic features particularly weight 
loss, anorexia and other cachexia related features (Kim et ah, 2003).
Approximately 20% of patients diagnosed with RCC present with paraneoplastic 
symptoms, with a flirther 10-40% developing these featui'es during their disease course 
(McDougal and Gamick, 1995). Paraneoplastic symptoms can include weight loss, 
hepatic dysfunction, anaemia, malaise, hypercalcaemia, anorexia, thrombocytosis, fever, 
night sweats, hypertension and erythrocytosis. Anaemia (52.1%), hepatic dysfunction 
(31.5%) and weight loss 22.9% represent the commonest paraneoplastic symptoms 
(Kim et al., 2003). Such presenting symptoms are also found in localised as well as 
metastatic RCC cases, suggesting that these findings reflect tumour biology rather than 
simply the local or distant extent of the tumour.
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These paraneoplastic symptoms may be the result of release of tumour 
associated proteins. The proteins responsible for the pai'aneoplastic effect may be shed 
directly from the tumour or generated by the immune system in response to the tumour. 
It has been suggested that cachexia and malaise may be due to the secretion of 
proinflammatory cytokines by the tumour infiltrating cells (Laski and Vugrin, 1987).
The general condition of a patient combining symptoms and co-morbidity has 
been shown to be an independent predictor of survival. An Eastern Cooperative 
Oncology Group (ECOG) performance status of 2 or greater is an independent 
prognostic factor associated with shorter survival and poorer response to 
immunotherapy (Lissoni et a l, 1994; Zisman et al., 2002).
The increased use of abdominal imaging has lead to a greater number of tumours 
being identified in the absence of symptoms and is thought to account for a degree of 
stage migration towards localised disease. In the 1970s only 10% of patients were 
diagnosed incidentally compared with 61% in the 1990s (Zisman et ah, 2001). 
Compared to symptomatic tumours it has been shown that tumours found fortuitously 
are of a lower histological grade and stage with a lower risk of métastasés and patients 
noted to survive longer (Bretheau et ah 1995; Tsui et ah, 2000).
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1.5 Assessment of renal cancer prior to treatment
Previously known as the “internists tumour” due to the presentation as various 
paraneoplastic phenomenon; it is now known as the “radiologists tumour” as increasing 
numbers o f  patients are diagnosed on incidental radiology. Therefore radiology has a 
role in diagnosis, staging, planning surgery and obtaining histological biopsy o f  renal 
lesions. Renal masses can be identified on plain radiograph, intravenous urography, 
ultrasound, magnetic resonance imaging (MRI) and computed tomography.
The greater access to ultrasound for most departments means that this modality 
commonly identifies incidental lesions and is highly sensitive in distinguishing between 
cystic and solid lesions (Helenon et a l ,  2001) Figure 1.6. To accurately characterise 
and plan treatment magnetic resonance imaging and computerised tomography are used 
to image renal masses.
8 20cm  
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Figure 1.7 An Ultrasound image of solid lesion arising from the right kidney 
(Patterson B et al., www.cortlandtforum.com).
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Computerised tomography scanning is the gold standard for diagnosis, 
characterisation and staging o f  renal tumours (Herts, 2003). Thin section helical 
computerised tomography reduces volume averaging, eliminates misregistration from 
respiratory or patient motion, and allows rapid scanning in different phases o f  contrast 
enhancement (Herts, 2003) Figure 1.7.
Figurel.8 A computerised tomography image of an enhancing solid renal mass 
arising from right kidney (arrowed) (Patterson B et al., www.cortlandtforum.com).
Traditional two phase contrast computerised tomography scanning includes a 
pre-contrast and a post-contrast scan. N ew  triphasic helical computerised tomography 
includes pre-contrast unenhanced phase (to assess for calculi and baseline attenuation), 
corticomedullary phase (timed to visualise vascular structures) and nephrographic phase 
(most sensitive in detecting and determining enhancement) (Yuh and Cohan, 1999). It 
is difficult to distinguish on computerised tomography between renal cell carcinoma and 
oncocytoma. Papillary lesions are suggested to enhance less than clear cell lesions 
(Jinzaki et a i ,  2000). The effective radiation dose for an abdominal computerised
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tomography scan is 2200 mrad which is over 7 times the annual natural background 
radiation of 300 mrad (Prasad et al., 2002).
Computerised tomography assessment not only has a role in diagnosis, but also 
in accurate staging of renal tumours. This staging accuracy approaches 91% (Catalano 
et al., 2003). Limitations exist, particularly when defining perinephric fat invasion, in 
distinguishing inflammatory changes from tumour infiltration (Johnson et ah, 1987). 
This means that accurately differentiating Tl/2 tumours from T3a is difficult and 
accounts for more than half of the staging errors using computerised tomography in 
assessment of renal tumours (Bechtold and Zagoria, 1997). Diffieulties also exist in 
defining accurately renal vein and caval involvement where flow artefact may occur.
The prognosis of patients with nodal disease is significantly poorer when 
compared to those without lymph node métastasés. Computerised tomography has a 
reported sensitivity of 83% and specificity of 88% in identifying lymphadenopathy in 
patients with renal cell carcinoma (Johnson et al., 1987). Direct invasion of adjacent 
organs in stage 4 disease can be difficult as 15% of patients can demonstrate obliteration 
of the fat plane and the adjacent organ without actual involvement (Catalano et al., 
2003).
Distant spread is accurately assessed using computerised tomography scanning. 
The most common sites of métastasés are the lungs, lymph-nodes, liver and bone but 
can occur anywhere throughout the body. Using lung settings pulmonary métastasés 
can be readily seen as solid pulmonary nodules, but to accurately define liver lesions 
arterial phase scanning is required to increase the sensitivity (Yoon and Herts, 2003).
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Surgical Planning
Helical computerised tomography with three dimensional image post processing 
has been shown to be accurate and reliable in illustrating the relative position within a 
kidney of a mass being considered for surgery (Coll et ah, 2000). This has particular 
use when planning nephron sparing surgery. 3-Dimensional reconstruction 
demonstrates the renal vasculatui*e accurately removing the requirement for pre­
operative angiography (Roy et aL, 1999). Magnetic resonance imaging can be used to 
characterise renal lesions in patients with renal insufficiency or contrast allergy as it can 
be performed both with and without gadolinium contrast agents that are not 
nephrotoxic. It is more sensitive than computerised tomography where contrast 
enhancement is equivocal and is better in assessment of renal vein and inferior vena 
cava tumour extension (Remer et aL, 2000).
In addition to planning nephron-sparing sur gery imaging can be used to assist in 
gaining satisfactory clearance and preserve optimal renal function. The use of 
intraoperative ultrasound is advised to allow precise determination of the extent of renal 
lesions and polycentricity (Marshall et aL, 1992; Assimos et aL, 1991). It is also 
reported to assist in accurate assessment of the feasibility of partial nephrectomy 
intraoperatively. Ultrasound scanning provides a guide to more accurate nephrotomy, 
facilitating the attainment of negative resection margins during partial nephrectomy 
(Assimos et aL, 1991).
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Positron Emission Tomography
This is an experimental modality of renal cancer imaging and operates on the 
principle of an increased rate of glycolysis in cancer cell. A radioactive positron- 
emitting analogue of glucose (fluorine-2-D-deoxyglucose) is taken up and 
phosphorylated in cells to remain trapped and detectable using a detector ring. The role 
in renal cancer is emerging. It is good at initially identifying disease and better than 
conventional imaging at assessing local disease recurrence and metastatic disease (Hain 
and Maisey, 2003).
Radiological Guided Biopsy
Despite the advances in radiological imaging a number of solid renal lesions will 
turn out to be benign tumours of the kidney. The standard treatment for such solid 
lesions is either partial or radical nephrectomy with formal histology only obtained after 
surgery. Studies to examine the role of fine needle biopsy have demonstrated an 
excellent positive predictive value for carcinoma on biopsy of greater than 94% (Dechet 
et aL, 1999). Unfortunately overall accuracy is only 75% with the greatest degree of 
error in defining benign lesions, therefore the standard of caie remains to remove these 
lesions without requirement of pre-operative biopsy. The principle role remains in 
excluding other rare causes of a renal mass, or in gaining positive histology in the 
absence of nephrectomy prior to commencing systemic treatment.
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1.6 Management of Renal Cell Carcinoma
1.6.1 Localised Disease
Surgery remains the only proven cure for localised renal cancer. Robson 
demonstrated that the removal of perinephric tissue, including the ipsilateral adrenal 
gland and lymphatic drainage including paracaval or para-aortic lymph nodes, was 
associated with better survival than simple nephrectomy (Robson et aL, 1969).
Robson’s original operation has been modified since it was first described, to 
reflect the observed lack of survival benefit achieved in routine removal of the 
ipsilateral adrenal gland. Sagalowski and coworkers (1994) demonstrated that the 
routine removal of the ipsilateral adrenal gland could contribute to cure in only 0.43% 
of all patients, and suggested that adrenalectomy be reserved for patients with large 
upper pole tumours.
With emerging technology and advances in surgery there has been a drive to 
provide an alternative surgical procedure to minimise the relative morbidity of formal 
open radical nephrectomy. The first described laparoscopic nephrectomy was carried 
out in 1990 at Washington University by daym an et al (daym an et aL, 1991). A total 
nephrectomy was performed removing the kidney, most of Gerota’s fascia and peri­
renal fat, with the adrenal left behind. Subsequent groups have extended the procedure, 
to more closely define laparoscopically the radical nephrectomy described by Robson, 
by including the adrenal, perinephric fat and Gerota’s fascia in the dissection (Dumi et 
aL, 2000; Ono et aL, 2001; Barrett et aL, 1998; Abbou et aL, 1999). Various 
adaptations have been described using retroperitoneal or transperltoneal approaches, as 
well as hand assisted procedures. This closer approximation in gross resection has led 
to the comparison of long term cancer free sui'vival with open radical nephrectomy.
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Portis and colleagues (2002), compared patients undergoing laparoscopic radical 
nephrectomy with a representative group of patients undergoing open radical 
nephrectomy within the same institutions, with a mean follow up of 54 months. The 
result was no significant difference in 5-year disease free survival or overall survival, 
but this study was carried out retrospectively with relatively small numbers. Other 
centres have shown similar results for short term data, but to date no formal randomised 
controlled study has been performed to compare cancer specific suivival following 
laparoscopic versus open radical nephrectomy.
Nephron-sparing surgery, or partial nephrectomy has evolved primarily for the 
treatment of patients who would otherwise be rendered anephric by traditional radical 
neplirectomy. Such patients include those with renal cell carcinoma arising in an 
anatomically or functionally solitai'y kidney, or alternatively in patients with bilateral 
synchronous renal lesions. The indications have extended to patients with solid renal 
lesions in whom the contra lateral kidney is threatened by local, systemic or genetic 
conditions that may affect its future function.
Data are accumulating to suggest that preservation of renal function can be 
achieved following partial nephrectomy without sacrificing cancer control (Uzzo et aL, 
2001). Current evidence suggests that adequate surgical clearance of RCC can be 
achieved with a minimal margin of 5 millimetres, as opposed to the previous 
recommended margins of 10-20 millimeters (Sutherland et aL, 2002). Having 
confirmed intraoperative clear- margins local recuiTence is unlikely, which essentially 
assures local cancer eontrol. Sutherland and colleagues (2002) describe no cases of 
local recurrence with negative margins.
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The excellent results reported following nephron sparing surgery in patients with 
a normal contra lateral kidney has led to the suggestion that in selected patients this 
treatment can be extended to such patients on an elective indication (Butler et aL, 1995; 
Lemer et aL, 1996). Concerns exist regaining the impact of tumour size on patient 
survival and localised recuiTence after partial nephrectomy. Following a large study at 
the Cleveland Clinic examining 485 patients it was observed that a significantly lower 
rate of recurrence and significantly improved survival after nephron sparing surgery for 
tumours 4cm or less compared with those greater than 4cm (Hafez et aL, 1999). 
Accordingly this guideline is increasingly accepted that elective partial nephrectomy 
should be offered only to patient with tumours less than 4cm.
Further to the development of open partial nephrectomy there are a number of 
current experimental techniques under investigation to provide yet more nephron 
sparing minimally invasive options in the management of small, localised tumours. 
These include laparoscopic partial nephrectomy (Rassweler et aL, 2000), and a variety 
of energy based tissue ablative procedures like cryoablation (Gill et aL, 2000), 
radiofrequency ablation (Gill et al 2000), high intensity focussed ultr-asoimd (Chapelon 
et aL, 1992), microwave thermotherapy (Kigure et aL, 1996), and interstitial photon 
irradiation (Chan et aL, 1999). None of these treatments are of proven efficacy, much 
of the studies having been carried out in animal models and further work will have to be 
performed before any conclusions can be drawn with regard to their place in treatment 
of renal cancer.
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1.6.2 Management of Metastatic Disease 
Immnnotheranv
Metastatic renal cancer remains highly resistant to systemic therapy with no 
proven cure in advanced disease (Motzer and Russo, 2000). Immunotherapy with 
interleukin 2 and/ or interferon-a achieves response in 10-20% of patients, only a very 
small number of which are durable (Motzer et aL, 1997; Fisher et aL, 1997). Most 
studies define response to treatment as either static disease of tumour regression, with 
complete response accounting for only a very small number of patients.
The median survival of patients on interferon therapy is 8.5 months compared 
with 6 months for patients given medroxyprogesterone acetate (Bower et aL, 1998). In 
those patients who respond (12%) longer survival is associated with high performance 
status, prior neplnectomy and predominantly lung métastasés (Minasian et aL, 1993; 
Fossa et aL, 1991). Duration of response rarely exceeds 2 years (Motzer and Russo, 
2000). Treatment dosage and duration vary between trials. A dose of 5 to 20 million 
units of recombinant interferon daily is thought to have maximal efficacy without the 
toxicity of the higher doses (Kiown, 1987). Any marginal benefit in overall sui'vival 
must be weighed against the toxic side effects of interferon which can be severe 
including general malaise, fevers, rigors, anorexia and nausea,
Interleukin-2 has been shown to achieve complete and partial responses in 19% 
of patients with a median duiation of response of 22 months (Bower et aL, 1998). 
Bolus Interleukin-2 is notably more toxic than interferon and has an associated 
treatment-related mortality of 4%.
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Combination regimens have been suggested to have greater response rates 
compared to single agent interferon or interleukin-2 (Negrier et aL, 1998). Negrier and 
co-workers (1998) demonstrated objective response in 19% of patients on combination 
treatment compared with 7% and 8% for interleukin-2 and interferon respectively. 
Overall survival was not significantly different in this study with the combination arm 
experiencing greater toxicities. Chemotherapy in isolation has no proven benefit in the 
treatment of renal cell carcinoma. Evidence is emerging that 5-fluorouracil in 
combination with immunotherapy does improve response rates (Samland et aL, 1999). 
Current investigations into the response rates for combination treatment including 
interferon, 5-fluorouracil and interleukin-2 versus single agent interferon are ongoing in 
the EORTC RE04 trial.
Immunotherapy has been considered in an adjuvant role in treating patients at 
high risk of relapse after surgery. To date studies have failed to demonstrate significant 
survival benefit using adjuvant immunotherapy (Blasting et aL, 1999). The lack of 
prospective data prompted the EORTC adjuvant renal study to be caiiied out, but this 
has had to be halted due to poor patient recruitment.
Radiotherapv
Renal cell carcinoma is historically regarded as a radio-resistant tumour, but 
evidence continues to indicate a role for radiotherapy in the palliation of symptoms. 
Radiotherapy has most commonly been used in the treatment of symptomatic 
métastasés to bone and brain, but may also be used in lung, spinal cord and soft tissue 
(Onufrey and Mohiuddin, 1985). Radiotherapy can achieve a palliative response in 
86% of patients and a complete palliative response in 49% (DiBiase et aL, 1997).
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Response rates ai'C noted to be higher in those patients with better performance status 
and those receiving a higher biologically active effective dose (greater than 50Gy).
Cvtoreductive Nenhrectomv
With the increase in understanding of the biology of renal tumouis has come a 
move towards cytoreductive nephrectomy. In the late 1970s before the advent of 
immunotherapy the natural history of metastatic renal carcinoma was not affected by 
adjunctive nephrectomy (de Kernion et al., 1978). At this time nephrectomy was 
considered as debulking surgery and principally management of significant symptoms 
such as haematuria and loin pain. Currently there is increasing evidence to suggest that 
de-bulking of renal cell carcinoma may actually remove tumour growth associated 
factors (eg transforming growth factor beta) which are potent immunosuppressive 
factors and which, when, removed, make the host more capable of responding to 
systemic immunological treatment (Filgin, 1999).
Studies have compared immunotherapy regimens along with cytoreductive 
nephrectomy and have demonstrated an improved survival benefit. The University of 
California-Los Angeles group compai’ed their experience with interleukin-2 
immunotherapy after cytoreductive nephrectomy with matched interferon plus 
nephrectomy cases (Pantuck et al., 2002). This study demonstrated a 30% improvement 
in both groups with 5 year survival a 19.6% in the 11-2 + nephrectomy group compared 
with 10% in the IFN + nephrectomy group. This study also demonstrated a doubling of 
survival compared with the interferon only group.
Concerns exist regarding the timing of nephrectomy due to the associated 
morbidity and perioperative mortality along with the potential for patients to not recover 
sufficiently to undergo systemic immunotherapy. Due to these concerns it has been
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suggested that nephrectomy be reserved only for those patients who demonstrate a 
response to immunotherapy prior to nephrectomy. Levy and coworkers (1998) report 
3% peri-operative mortality with 82% of patients proceeding to immunotherapy in 
carefully selected patients. In an attempt to reduce the prolonged recovery period and 
morbidity after open nephrectomy the role of laparoscopic procedures has been 
proposed in the cytoreductive setting.
The current recommendations from South West Oncology Group state that in 
suitable patients (especially those with a good performance status), nephrectomy 
followed by immunotherapy using interferon [alpha]-2b with or without other cytokine 
therapy should be the control arm for future phase 111 trials (Yonover and Flannigan, 
2000).
Metastasectomv
The resistance of renal cancer to traditional systemic chemotherapy, combined 
with the poor sustained response rates to immunotherapy, has lead to the exploration of 
treatment, where métastasés appear to be isolated, of sui'gical metastasectomy. In this 
special, small subgroup of patients several studies have demonstrated prolonged 
survival following removal of solitary métastasés.
Post mortem data demonstrates single organ confined métastasés to occur with 
a frequency of 8 -  11% (Saitoh et a l, 1982). The lung is the commonest site of 
métastasés, and where identified in isolation, confers the best prognosis following 
metastasectomy increasing median survival to 43 months (Maldazys and deKiemon 
1986; Van Der Poel et a l, 1999; Piitz et a l, 2002). Bone is the second commonest 
resectable site for renal carcinoma to occur, with between 15 and 30% of skeletal
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métastasés thought to be solitary, but confers a poorer prognosis (Maldazys et a l, 
1986).
Solitary brain métastasés account for 8.1% of solitary métastasés seen in relation 
to renal cancer. Those younger patients, with good performance status, demonstrate the 
most benefit from surgery with a median survival of 15.3 months versus 10.3 months 
treated with radiotherapy (Pomer et a l, 1997).
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1.7 Prognosis of Renal Cell Carcinoma
1.7.1 Pathological criteria
The extent of anatomical extension of disease is one of the principle prognostic 
factors in renal cancer, as with many other tumours. Stage was originally defined 
according to Robson’s criteria, but today a more refined TNM system is preferred 
(Table 1.3, 1.4) (Robson et al., 1969; American Joint Committee on Cancer 2002). 
There have been a number of changes in the system between 1987 and 2003, which 
principally involve the stratification between T1 and T2 lesions. T1 lesions prior to 
1997 were 2.5 cm or less with greater confined lesions all being T2. In 1997 the size of 
T1 lesions was increased to 7cm or less but concerns arose relating to significant 
variability in clinical outcome within this group (Zisman et ah, 2001). Accordingly the 
American Joint Committee on Cancer 6^*^ edition of TNM staging has subdivided T1 
lesions into T la  <4cm and Tib >4cm < 7cm.
The presence of venous invasion confers a poorer prognosis than those patients 
with lesions confined to the kidney (Giberti et al., 1997). Studies have suggested that 
the presence of renal vein or caval involvement associated with invasion of the vessel 
wall carries an even higher rate of recurrence. Van-poppell and co workers (1997) 
demonstrated a 45% recurrence rate at one year post nephrectomy where micro vascular 
invasion was present.
Microvascular invasion has been shown to be correlated with disease 
progression but is not an independent prognostic factor (Lang et a l, 2000). It is also 
been reported that disease invasion into the veins of the renal sinus may identify patients 
at risk of metastatic progression even when the tumoui’ is confined to the kidney 
(Bosnib et al., 2000). This is reflected in the new TNM guidelines (Table 1.3).
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Lymphadenectomy is not routinely performed in the absence of enlarged nodes 
detected prior to surgery. Several studies have demonstrated that such regional lymph 
node dissection in patients with clinically negative nodes is umiecessaiy and offers 
limited staging infoimation and no benefit in terms of decreasing disease recurrence or 
improving suivival (Minervini et ah, 2001; Pantuck et a t, 2003). In patients with 
positive lymph nodes on preoperative staging, dissection is however associated with 
improved suivival in carefully selected patients undergoing cytoreductive neplirectomy 
and post operative immunotherapy (Pantuck et ah, 2003).
Stage specific survival as reported by the US National Cancer Database is shown 
in Table 1.5. These are overall survival rates and do not account for other prognostic 
factors such as tumour grade, histological subtype, patient age or treatment modality 
(Marshall et aL, 1997). For those patients managed with nephi’ectomy the survival is 
significantly higher than overall data would suggest, particularly for localised tumours 
confined to the kidney. Five year cancer specific survival rates for T1 (Tla + Tib) and 
T2 lesions treated by open radical nephrectomy are reported at 95% and 87% 
respectively (Portis et a l, 2002). In further subdividing pTl lesions 3 and 10 year 
survival for pTla lesions is 98.6% and 86.5% respectively. For pTlb the suiwival rates 
are 93.7% and 87.9% (Masuda et a l, 2003).
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Table 1.3 TNM classification of renal tumours according to the American
Joint Committee on Cancer 6**^ edition of TNM staging.
T Tx Tumom* not assessable
TO Absence of tumour
T la Tumour less than or equal to 4cm limited to the kidney
Tib Tumoui* greater than 4cm up to 7cm limited to the kidney
T2 Tumour greater than 7cm limited to the kidney
T3a Invasion of the perirenal fat, renal sinus invasion or adrenal gland
T3b Invasion of the renal vein or subdiaphragmatic inferior vena cava
T3c Invasion of the supradiphragmatic vena cava
T4 Tumour invasion of Gerota’s fascia
N Nx Lymph nodes not assessable
NO Absence of lymph node métastasés
NI Only 1 lymph node metastasis
N2 Several lymph node métastasés
M MO Absence of distant metastasis
Ml Distant métastasés
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Table 1.4 Stage grouping according to American Joint Committee on Cancer 
6*^  Edition TNM Staging.
Stage I T1 NO MO
Stage II T2 NO MO
Stage III T1 N1 MO
T2 N1 MO
T3 NO/1 MO
Stage IV T4 NO/1 MO
Any T N2 MO
Any T Any N Ml
Table 1.5 Five-year cumulative relative survival rates by AJCC/ UlCC stage a
diagnosis.
Years After 1 2 3 4 5
Diagnosis
% Stage 1 95 91 90 87 85
Survival Stage 11 94 90 87 85 83
Stage 111 83 73 68 63 60
Stage IV 37 23 17 13 11
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1.7.2 Performance Status
Currently the most commonly used measure for performance status is the 
Eastern Cooperative Oncology Group ECOG-ps, which defines the ability to perform 
the daily activities of life, such as house-work and self care (Table 1.6). Several studies 
have demonstrated that a poorer performance status has a negative impact on survival 
(Elson et al., 1988; Giberti et ah, 1997). This has been observed in both localised 
tumouis predicting recunence and in metastatic disease in predicting response to 
immunotherapy (Zisman et ah, 2002).
It is unclear in localised disease whether it is because the performance status is 
low that the response to surgery is less effective or whether the performance status is 
low because the tumour is more aggressive. In metastatic disease it has been suggested 
that the reason for poorer outcome with reduced performance status is principally 
related to the fact that these patients receive significantly less chemotherapy and 
develop more toxicities rather than a specific reduced response to treatment (Andreyev 
et al.,. 1998). The effect of performance status on overall survival has been utilised in 
stratifying patients according to overall risk in the University of Califomia-Los Angeles 
group Integrated Staging System (UISS) (Zisman et ah, 2002 Table 1.7). This 
prognostic algorithm combines stage, grade and perfoimance status to predict overall 
outcome in both metastatic and localised disease.
Performance status does not fully take into account other symptoms related to 
the tumour such as cachexia. As cachexia like symptoms have been demonstrated to be 
independent prognostic factors it has been suggested that ECOG-ps should be expanded 
to include these parameters (Kim et ah, 2003).
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Table 1.6 Eastern Cooperative Oncology Group Performance Status (ECOG- 
ps) scale.
Performance
Status
Criteria
0 Fully active, able to carry on all pre-diseases performance 
without restriction. (Kamofsky 90-100)
1 Restricted physically in strenuous activity but ambulatory and 
able to carry out work of a light or sedentary nature (eg light 
housework, office work). (Karnofsky 70-80)
2 Ambulatory and capable of all self care but unable to carry out 
any work activities. Up and about more than 50% of waking 
houi's. (Karnofsky 50-60)
3 Capable of only limited self care, confined to bed or chair more 
than 50% of waking hours. (Kamofsky 30-40)
4 Completely disabled. Cannot caiTy out any self caie. Totally 
confined to bed or chair. (Karnofsky 10-20)
Table 1.7 The UISS Prognostic algorithm (Zisman et al. 2002).
1.7.1 NO, MO nephrectomised patients
T Stage 1 2 3 4
Grade 1-2 3-4 Any 1 >1 Any
ECOG 0 >1 0 >1 Any 0 >1 0 >1 Any
Risk Low Intermediate (]nt) High
1.7.2 N I, N2 or Ml nephrectomised patients.
Stage NIMO N2M0/ Ml
Grade Any 1 2 3 4
ECOG Any 0 >1 0 >1 0 >1 0 >1
Risk Low Int Low Int High
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1.8 The Inflammatory Response
As previously discussed the principle management strategy in metastatic disease 
is recruitment of host immunity using interferon or interleukin-2 immunotherapy. 
Immunotherapy has been shown to have a direct inhibitory effect on tumour cell 
growth/ functions including down-regulation of oncogene expression and induction of 
tumoui* suppressor genes (Pfeffer et al., 1998). Additionally immunotherapy can 
increase major histocompatibilty complex 1 expression which combined with the effect 
of increased natural killer cell and T cell activity results in enhanced tumour cell 
recognition (Takahashi et al., 1994; Pfeffer et ah, 1998). The resistance of renal cancer 
to respond to treatments other than immunotherapy would suggest that the inflammatory 
immune response is of paiticular relevance in development and progression of renal cell 
carcinoma.
It is now recognised that both the local and systemic inflammatory response play 
a crucial role in neoplastic development and the progression of many tumours 
(Coussens and Werb, 2002). Inflammation involves the activation of many promoters 
involved in cell proliferation, production of reactive oxidative species leading to 
oxidative DNA damage as well as recruiting many chemokines involved in cell 
migration and adhesion. In normal inflammation this process is self-limiting, but where 
tumour formation occurs it appears to persist. The reason for this continued response is 
not known, however there is evidence that a variety of cytokines and chemokines are 
produced by the host and the tumour cells. The resultant inflammatory component of a 
developing neoplasm includes a diverse leukocyte population of lymphocytes, 
neutrophils, dendritic cells, macrophages, eosinophils and mast cells.
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1.8.1 The Systemic Inflammatory Response
1.8.1.1 Serum C-Reactive Protein
C-reactive protein is a 130kDa acute phase protein synthesised in the liver and 
constructed of five polypeptide subunits. It is present in minute quantities in normal 
serum (<lmg/L) and is thought to mediate binding of foreign polysaccharides, 
phospholipids, complex polyions and also activating complement via the classical 
pathway (Baynes and Dominiczak, 1999).
Interleukin-6 is the cytokine most likely to be responsible for elevated C- 
reactive protein levels in patients with renal cancer (Blay et al., 1992). Elevated 
interleukin-6 and consequently elevated C-reactive protein are markers of a poor 
response to immunotherapy (Blay et al, 1992).
C-reactive protein levels have been examined in patients undergoing 
cytoreductive nephrectomy. Patients with an elevated C-reactive protein treated with 
cytoreductive nephrectomy in addition to immunotherapy have been suggested to do 
better than patients with an elevated C-reactive protein treated with immunotherapy 
alone (Fujikawa et a l, 1999). Furthermore patients in whom postoperative serum C- 
reactive protein decreases to within normal limits are observed too have a better 
prognosis than those in whom it remained elevated (Fujikawa et ah, 1999).
Cytoreductive nephrectomy may decrease the total amount of interleukin-6 
secretion by the tumour and improve the response to iimnunotherapy. Patients with an 
elevated postoperative nadir C-reactive protein may signify interleukin-6 secretion at a 
higher rate from metastatic lesions. These patients therefore have biologically more 
aggressive lesions and are less responsive to immunotherapy compared with those who 
show a decline to normal C-reactive protein postoperatively. The same study also noted
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that patients with a normal C-reactive protein undergoing cytoreductive nephrectomy 
did no better than patients with a normal C-reactive protein treated by immunotherapy 
alone, suggesting surgery is of greatest benefit in patients with evidence of an 
inflammatory response (Fujikawa et al., 1999).
1.8.2 The Local Inflammatorv Response
1.8.2.1 Tumour Lymphocytic Infiltrate
The presence of a significant tumour mononuclear cellular infiltrate is thought to 
be evidence of the host attempting to mount a local cell mediated immune response 
(Schendel et al., 1993). This response, in the later stages at least, is insufficient to 
prevent tumour* growth and fails to stop progression.
The characteristics of the lymphocytic tumour infiltrate associated with better 
outcome and prognosis have been defined in a number of solid tumouis. Increased 
tumour T-lymphocyte CDS subsets have been shown to be associated with better 
survival in colorectal cancer (Naito et al., 1998). Conversely, greater numbers of CD8+ 
and CD4+ T lymphocytes are associated with increased tumour recurrence and poorer 
survival in patients with renal cell carcinoma (Kolbeck et a l, 1992; Nakano et al, 2001, 
Bromwich et al, 2003). This relationship, opposite to that observed in other solid 
tumours, suggests that the tumour infiltrate in renal cancer is more likely to be 
ineffective in mounting host anti-tumour immunity.
There are two distinct subsets of CD4+ T helper (Th) cells differentiated from 
one another according to their cytokine profile. Only Thl cells produce interleukin - 2, 
interferon-[gamma] and tumour necrosis factor -[beta] which are principally associated 
with cytotoxic lymphocyte activation (Cher and Mosmann, 1987). Th2 cells produce
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interleukin-4, interleukin-5, interleukin-6 and interleukin-10 and are associated with 
humoral immunity and cytotoxic lymphocyte suppression (Stevens et al., 1988; Steiner 
et al., 1999).
The major goal of immunotherapy in the treatment of renal cancer is the 
activation of T helper cells and cytotoxic CD8+ lymphocytes. Studies examining the 
intratumoral immunological environment in patients with renal cancer have shown a 
tendency to produce Th-2 related cytokines in accordance with stage and grade of 
tumour (Onishi et al., 1999). These results are consistent with the work suggesting that 
higher numbers of infiltrating T-lymphocytes confers a poorer prognosis as the infiltrate 
is not effective in recruiting an appropriate cell mediated response.
The precise nature by which the immune response, innate or acquired, is 
rendered inadequate is uncleai*. In renal cancer it may be due to immune suppressor 
agent shedding, induction of T-cell apoptosis or aberrant or inadequate expression of 
major histocompatibility antigens on the tumour cell surface (Uzzo et al., 1999; Akdis 
and Blaser, 2001).
1.8.2.2 Interleukin-6
Interleukin-6 is a cytokine of approximately 26kD, which is synthesised by 
mononuclear phagocytes, vascular* endothelial cells, fibroblasts and other cells in 
response to Interleukin-1 and tumour* necrosis factor. It functions as a pro-inflammatory 
cytokine and induces hepatocytes to synthesise acute phase proteins, which compliment 
the proteins induced by interleukin-1 and tumour necrosis factor. It also acts as a 
cellular growth factor, initially described in relation to plasma B cells but has also been 
shown to be a co-stimulator in the growth of bone marrow and stem cells.
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The presence of interleukin-6 mRNA and active secretion has been 
demonstrated in freshly isolated renal cancer tissues (Miki et al., 1989). Further studies 
have revealed renal cancer cell lines to express mRNA for both interleukin-6 and its 
receptor (Takenawa et ah, 1991). Patients with liigher mRNA levels are noted to have a 
greater incidence of both lymph node and distant métastasés. Blay and co workers 
(1992) have proposed that interleukin-6 acts as an autocrine growth factor, and 
correlates well with serum C-reactive protein concentrations. This suggests that 
interleukin-6 is the pro-inflammatory cytokine most closely associated with increased 
C-reactive protein production. This work has identified patients with a poorer prognosis 
as having detectable serum interleukin-6 and C-reactive protein greater than 50. 
Yoshida and co workers (2002) as well as confirming the close correlation with C- 
reactive protein, also noted significantly higher interleukin-6 levels with stage IV 
tumours, G3 tumours and a positive correlation with tumour size.
The source of interleukin-6 production in renal cell caicinoma has not been 
satisfactorily identified in vivo. Miki and co workers (1989) using immunostaining 
techniques in cell lines identified 2-9% of cultured cells to positively stain for anti- 
interIeukin-6 antibody. Direct staining of renal cancer tissues for interleukin-6 to 
differentiate between the vascular endothelial cells and renal carcinoma cells, has shown 
that 70% of tumour cells themselves stain positively for interleukin-6 expression 
(Takenawa et ah, 1991; Paule et ah, 2000). These studies did not relate direct tissue 
positive staining to serum interleukin-6 concentrations.
Interleukin-6 is therefore implicated in the inflammatory response, which 
confers a poorer prognosis, and would seem to be stage dependent. C-reactive protein 
would appear to be produced in response to interleukin-6 hepatocyte stimulation as a
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principal acute phase protein. It has been suggested that interIeukin-6 acts as an 
autocrine growth factor secreted by renal cancer cells, however its mechanism of action 
has not been fully identified.
1.8.2.3 InterIeukin-6 Receptor
Inteiieukin-6 function is mediated by two membrane proteins, a 80kDa binding 
receptor and the gpl30 protein that transduces the signal (Kishimoto, 1989). Soluble 
gp80 binds to interleukin-6 and the interleukin-6/ soluble interleukin-6 receptor 
complex binds and activates the gpl30 transducer chain (Yasukawa et ah, 1990). 
Previous work has shown interleukin-6 receptor expression in 26% of renal cancers 
(Takenawa et ah, 1991).
Further work to define interleukin-6 receptor expression using 
immunohistochemistry demonstrated again 26% of renal cancer patients to express 
interleukin-6 receptor. Also, 83% of patients with metastatic disease were positive for 
the receptor (Costes et al., 1997). In this study interleukin-6 receptor expression was 
associated with increasing tumour stage, higher grade, greater proliferative index and 
detectable serum interleukin-6. Interleukin-6 receptor is a marker of patients with more 
aggressive disease and is the mediator of interIeukin-6 function which is known to 
confer a poorer prognosis.
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1.8.2.4 Cyclo-oxygenase 2
Arachidonic acid metabolism is of fundamental importance in inflammation. 
Primary inflammatory cytokines such as tumour necrosis factor a , interleukin-la, 
interleukin-Ip and consequently interleukin-6 induce the cyco-oxygenase-2 gene to 
produce cyclo-oxygenase-2 enzyme. This enzyme synthesises pro-inflammatory 
prostaglandins (Dinarello., 1995).
Cyclo-oxygenase-2 is one of two cyclo-oxygenase isoforms, cyclo-oxygenase 1 
& 2, which posses many similar enzymatic properties, however differ in many ways. 
Cyclo-oxygenase 1 is constitutively expressed, however in the normal adult cyclo- 
oxygenase-2 is principally confined to the macula densa of the kidney and the brain. 
Cyclo-oxygenase-2 is up regulated in response to growth factors, tumour promoters and 
cytokines, and appears to be the isoform most intrinsically related to acute inflammatory 
responses (Herschman et aL, 1996). Oncogenes have also been noted to result in cyclo- 
oxygenase-2 expression including v-src, HER2/neu, Wntl and v-Ha-ras (Fosslien., 
2000).
Expression of cyclo-oxygenase-2 can be induced through binding at the 
promoter region of the gene located on chromosome lq25.2-3. These binding sites 
include those for nuclear factor-kappa B, cyclic AMP response element motifs, 
transforming growth factor-B response elements and nuclear factor interleukin-6 motifs 
(Chen et ah, 1999). Several elements are thought to act through this induction region 
including epidermal growth factor, transform growth factor-B, intracellular nitric oxide 
synthase, benzo[a]pyrene, interleukin-6 and androgens. Tumour necrosis factor a  and 
interleukin-1 act to directly induce nuclear factor-kappa B which promotes cyclo- 
oxygenase-2 transcription.
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Cyclo-oxygenase-2 and Neoplasia
Cyclo-oxygenase-2 over expression was first identified in colorectal carcinoma 
when compared to undetectable levels found in normal mucosa (Eberhart et ah, 1994). 
Subsequently aberrant cyclo-oxygenase-2 expression has now been identified in cancers 
affecting numerous organs, including lung, pancreas, stomach, oesophagus, prostate, 
bladder, cervix, skin and head and neck (Dannenberg et ah, 2001). Cyclo-oxygenase-2 
is also implicated early in tumour genesis, as demonstrated in rodent models of 
intestinal tumour genesis, where premalignant adenomas are noted to express cyclo- 
oxygenase-2 (Boolbol et ah, 1996).
This implication of cyclo-oxygenase-2 mediated inflammation and tumour 
genesis has been highlighted in epidemiological studies examining the incidence of 
carcinoma in people regularly using non steroidal anti-inflammatory drugs which inhibit 
cyclo-oxygenase. Long term follow up over 35 years of patients treated with non­
aspirin non steroidal anti-inflammatory drugs for at least 48 months had half the 
expected level of colorectal carcinoma development than the normal population (Cibere 
et ah, 1997).
Cyclo-oxygenase-2 is thought to mediate its effect on cancer foimation via the 
formation of prostaglandins, in particular prostaglandin E2. These prostaglandins as 
well as having direct effects on cell proliferation are also thought to interfere with 
apoptosis, hence adding to tumour growth (Bandyopadhyay et aï,, 1987). This 
impairment of apoptosis is thought to derive from increased levels of Bcl-2 secondary to 
prostaglandin synthesis (Sheng et ah, 1998). Bcl-2 expression facilitates closure of 
mitochondrial pores which prevents the escape of cytochrome c hence prevents normal 
apoptosis.
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As well as preventing apoptosis cyclo-oxygenase-2 can have an inhibitory effect 
on E-cadherin to facilitate cell migration and invasion. It also induces hepatocyte 
growth factor production by surrounding stromal cells which enhances invasion, 
métastasés and angiogenesis as well as functioning in a positive feedback mechanism in 
cyclo-oxygenase-2 induction (Hori et a l, 1993). Prostaglandins also increase the 
production of interleukin-6 foiming a positive feedback loop supporting the potential 
autocrine growth function of this cytokine in renal cancer.
Cyclo-oxygenase-2 and Renal Cancer
Cyclo-oxygenase-2 is expressed in the normal kidney and is an important 
mediator of renal function. This makes renal cancer unique among the other solid 
tumours in which cyclo-oxygenase-2 has been examined. It is expressed in the macula 
densa, cortical thick ascending limb, inner medullary collecting duct cells and 
intercalated cells in the renal cortex (Fergusson et ah, 1999; Harris, 2003).
Normal renal physiology requires the active production and metabolism of 
prostaglandins (Norian et al., 2002). Prostaglandin E2 (PGE2) is the most abundant 
form found in the renal tubules and regulates sodium and clrloride transport in the loop 
of Henle as well as modulating water transport and renal medullary blood flow. 
Prostaglandin 12 is the most abundant prostaglandin in the renal cortex and regulates 
renal vascular tone, glomerular* filtration rate and renin release (Dunn, 1984). Cyclo- 
oxygenase-2 is implicated in all of these processes.
The inflammatory response is associated with poor prognosis in renal cancer. 
The induction of cyclo-oxygenase-2 through inflammatory mediators, such as 
interleukin-6, would suggest likely enhanced cyclo-oxygenase-2 expression would be 
present in renal cancer tissue. Cyclo-oxygenase-2 is also induced by benzo[a]pyrene, a
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product of cigarette smoking, and androgens, via described nuclear factor kappa B 
activation pathways, both known risk factors in the development of renal cancer. These 
known carcinogens may result in the constitutive expression of nuclear factor kappa B, 
and accordingly promote the interplay of interleukin-6 and cyclo-oxygenase-2 as the 
final common pathway. But cyclo-oxygenase-2 is constitutively expressed by renal 
tubules in health.
To date there are little data on the relationship between cyclo-oxygenase-2 
expression and influence in renal cancer. The first study was reported in canine models, 
where increased expression was noted, and thought to represent cancer cells reverting to 
a less differentiated form (Khan et al., 2001). In the only published series on human 
tumours Miyata and co workers (2003) found that 53.4% of renal tumours expressed 
cyclo-oxygenase-2. This is in contrast with other tumours such as colorectal where 
higher levels of expression are observed in 80-90% of cancers (Tomozawa et al., 2000). 
With relation to prognosis cyclo-oxygenase-2 expression was not shown to be 
significantly associated with prognosis (Miyata et ah, 2003).
The implications of cyclo-oxygenase-2 expression in renal cancer are difficult to 
interpret due to its role in physiology. Should higher concentrations of interleukin-6 
along with abeiTant cyclo-oxygenase-2 expression be demonstrated this may indicate a 
potential point of intervention with cyclo-oxygenase-2 inhibitors. Cyclo-oxygenase-2 
inhibitors have been shown to decrease endothelial tubule formation in vitro, and it is 
from these cells that tumours are thought to arise in the kidney (Jones et al., 1999).
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1.9 Summary and Aims
In summary the inflammatory mechanisms of tumour development are as yet 
poorly understood in relation to renal cancer. The systemic inflammatory response, 
evidenced by elevated C-reactive protein concentration, would appear to be of 
considerable importance in the relationship between tumour, host and prognosis. 
Preliminary work suggests that the lymphocytic infiltrate behaves in a different manner 
in renal cancer to other solid tumours. The link between this impaired T-lymphocytic 
response and the biologic nature of renal cancer cells may be mediated through the 
cytokine profile, in particular interleukin-6,
Precise localisation of pro-inflammatory cytokines to tumour* cells or 
inflammatory cells within the tumour, particularly in paraffin embedded tissues, 
remains problematical. However, interleukin-6 activity has been assessed by staining 
for IL-6 receptor expression in a variety of solid tumour s, including renal cancer (Costes 
et al., 1997). By staining the tumour specimen for interleukin-6 receptor and correlating 
this with systemic C-reactive protein measurements our aim would be to define if such 
association existed and hence the tumour* responsible for the systemic inflammatory 
response.
Infiltration of tumours with T- lymphocytes has been reliably demonstrated to 
have prognostic significance in a variety of solid tumours, including renal cancer 
(Nakano et al., 2001; Bromwich et al., 2003). No study to date has examined or 
demonstrated interleuikin-6 to be correlated with an impaired T lymphocytic response.
Central to the local inflammatory response is cyclooxygenase-2 and increased 
expression has been shown to be associated with poor sm*vival in a number of common 
solid tumours (Dannenberg et al., 2001; Subbaramaiah and Dannenberg 2003).Whether 
the effect of interleukin-6 is dictated by its activation of cyclo-oxygenase-2 is not
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known in renal cancer. Examination of cyclo-oxygenase-2 in renal cancer is of 
particular relevance when considering the intrinsic relationship between cyclo- 
oxygenase-2 and normal renal function.
Aims
1. To examine the relationship between the pre-operative systemic inflammatory 
response and cancer specific suiwival in patients undergoing potentially curative 
resection for renal clear cell cancer.
2. To examine the relationship between the systemic inflammatoiy response, 
tumour T-lymphocyte infiltration, interleukin-6 receptor and COX-2 expression 
and survival in patients undergoing resection for renal cancer
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Chapter 2
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2 THE RELATIONSHIP BETWEEN THE PRE-OPERATIVE
SYSTEMIC INFLAMMATORY RESPONSE AND CANCER SPECIFIC 
SURVIVAL IN PATIENTS UNDERGOING POTENTIALLY CURATIVE 
RESECTION FOR RENAL CLEAR CELL CANCER.
2.1 Introduction
The ideal prognostic score for patients undergoing potentially curative resection 
of a primary renal cancer should clearly distinguish those who will eventually succumb 
to the disease from those who ar e cured. While TNM stage has been widely used, it fails 
to provide clear separation between these groups. This has lead to the development of a 
number of cumulative prognostic scores including TNM stage. TNM stage has been 
combined with tumour grade and performance status to form the UCLA Integrated 
Staging System (UISS, Zisman et al., 2002).
It is recognised that, in addition to tumour stage and proliferative activity, 
disease progression is dependent on a complex interaction of the tumoui* and host 
inflammatory response (Balkwill and Mantovani, 2001; Coussens and Werb, 2002; 
Vakkila and Lotze, 2004). Recently, the systemic inflammatory response, as evidenced 
by elevated circulating concentrations of C-reactive protein, has been shown to be a 
stage independent prognostic factor in patients undergoing potentially curative resection 
for colorectal cancer (McMillan et a l, 2003), pancreatic cancer (Jamieson et a l, 2005) 
and urinary bladder cancer (Hilmy et a l, 2005).
The aim of the present study was to examine the prognostic value of the 
systemic inflammatory response in patients undergoing potentially curative resection for 
renal cancer.
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2.2 Patients and Methods
Patients with renal clear cell cancer, who, on the basis of surgical findings and 
pre-operative computed tomography of chest abdomen and pelvis underwent potentially 
curative resection between August 1996 and November 2004 in the West of Scotland, 
were included in the study. To be defined potentially curative post operative histology 
had to determine surgically clear margins and no pathological evidence of nodal 
involvement and no CT evidence of métastasés.
Data for 1996-2000 (n= 57) were collected retrospectively from the West of 
Scotland Renal Cancer Database hence are not truly sequential and that for 2001-2004 
(n= 43) consequential and prospectively. Clinical stage and performance status (Eastern 
Cooperative Oncology Group, ECOG-ps) were recorded prior to surgery. Also, routine 
laboratory measurement of C-reactive protein was carried out.
Patients were staged pathologically according to the 1997 UICC TNM 
classification of renal tumours (Sobin et al., 1997). Tumours were graded according to 
criteria set out by Fuhrman and co-workers (1982). Tumour stage, grade and ECOG-ps 
were collated into the UCLA Integrated Staging System (UISS, Zisman et al., 2002, 
Table 1.7.1).
The Research Ethics Committee of North Glasgow NHS Trust approved the
study.
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2.2.1 C-Reactive Protein Assay
Routine laboratory measurement of patient's serum for C-reactive protein 
concentration was performed. The limit of detection of the assay was a C-reactive 
protein concentration lower than 6mg/l. The coefficient of variation, over the range of 
measurement, was less than 5% as established by routine quality control procedures. C- 
reactive protein measurement of greater than lOmg/1 was considered to indicate the 
presence of systemic inflammatory response (O'Gorman et a l, 2000).
2.2.2 Statistical Analvsis
Comparisons between groups of patients were carried out using contingency 
table analysis (X^) as appropriate. Sui'vival analysis was performed using the Cox’s 
propoitional-hazai'ds model. Deaths up to the end of October 2005 were included in the 
analysis. Multivariate survival analysis was perfonned using a stepwise backward 
procedure to derive a final model of the variables that had a significant independent 
relationship with survival. To remove a variable from the model, the corresponding P- 
value had to be greater than 0.10. Analysis was performed using SPSS softwai'e (SPSS 
Inc., Chicago, XL, USA).
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2.3 Results
The chai'acteristics of patients with renal cancer who underwent potentially 
curative resection (n= 100) are shown in Table 2.1 and Appendix I. The majority were 
male, over the age of 60 years, had good performance status and were defined as UISS 
intermediate risk. Approximately 40% had an elevated C-reactive protein (>10mg/l).
The minimum follow-up was 12 months; the median follow-up of the survivors 
was 59 months. During this period 25 patients died; 18 patients of their cancer and 7 of 
intercurrent disease. On univariate survival analysis, sex (p-0.050), tumour stage 
(p<0.001), Fuhiman grade (p<0.001), UISS (p<0.001) and C-reactive protein (p<0.01) 
were significant predictors of cancer specific survival.
On multivariate analysis with sex, tumour stage, Fuhrman grade, performance 
status and C-reactive protein entered as covariates, only sex (HR 0.25, 95% Cl 0.06- 
0.99, p=0.048), Fuhrman grade (HR 2.91, 95% Cl 1.29-6.56, p=0.010) and C-reactive 
protein (HR 7.67, 95% Cl 1.64-35.84, p=0.010) were significant independent predictors 
of cancer specific smwival.
On multivariate analysis with sex, UISS and C-reactive protein entered as 
covariates, only UISS (HR 2.70, 95% Cl 1.00-7.30, p=0.050) and C-reactive protein 
(HR 4.00, 95% Cl 1.21-13.31, p=0.024) were significant independent predictors of 
cancer specific sui vival. A greater proportion of females compared with males had 
Fuhrman grade I tumours (10% vs 29%, p=0.030, Fisher's exact test).
The relationship between the systemic inflammatory response and the 
clinicopathological characteristics ai-e shown in Table 2.2. There was no significant 
difference in age or sex between the inflammatory and non-inflammatory groups. An 
elevated C-reactive protein was associated with a greater number of patients with
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advanced tumour stage (p<0.01), increased grade (p<0.05), poorer performance status 
(p<0.01) and consequently a high UISS (p<0.01). Those patients with an elevated pre­
operative C-reactive protein concentration (>10mg/l) had a mean cancer specific 
survival of 71 months compared with 96 months (p<0.001) in those patients with a C- 
reactive protein concentration in the noimal range (<10mg/l).
In those patients with a UISS risk classified as “low” or “intermediate” (n= 91) 
an elevated C-reactive protein concentration was associated with a decrease in cancer 
specific survival (p= 0.008, Figure 2.1).
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2.4 Discussion
Surgical resection remains the only prospect for long term survival in patients 
with renal clear cell cancer. Currently, in patients undergoing surgeiy prognosis is 
based on tumour stage and grade and performances status (UISS, Zisman et al., 2002).
In the present study the pre-operative measurement of C-reactive protein provided 
additional prognostic information.
To OUT' knowledge this is only the second study to examine the role C-reactive in 
predicting sui'vival following potentially curative resection for renal cancer, Masuda 
and colleagues (1998) in a retrospective study of 111 patients reported that C-reactive 
protein was a prognostic factor independent of tumour stage and grade. However, 
performance status was not considered and thresholds for C-reactive protein were not 
defined in the survival analysis.
Few studies have identified factors which give prognostic information in addition 
to the UISS criteria, namely T stage, Fuhrman grade and ECOG-ps, in patients 
undergoing potentially curative resection for renal cancer. Recently, Shvarts and 
coworkers (2005) reported that tumour p53 expression was related to Fuhrman grade 
and displaced it in multivariate analysis. Similarly, Lam and colleagues (2005) reported 
that tumour Ki-67, unlike carbonic anhydrase, was related to the degree of necrosis and 
had independent prognostic value. Further studies are required to deteimine whether an 
elevated C-reactive protein has prognostic value independent of these other biological 
factors, in particular Ki-67.
It has been previously shown that, in patients undergoing potentially cuiative 
surgery for colorectal and pancreatic cancer, approximately one third and one half 
respectively, of patients had elevated circulating concentration of C-reactive protein
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pre-operatively and that these patients had a significantly lower cancer specific survival 
(McMillan et al., 2003; Jamieson et al., 2005). It was of interest that, in the present 
study, the proportion of patients with an elevated pre-operative C-reactive protein 
concentration was similar and that these patients also had a poorer outcome.
It may be that because C-reactive protein concentration has prognostic value 
independent of UISS criteria, it might be added to these criteria to improve the 
prediction outcome, in particular the large group of “low or intermediate risk” patients 
with renal cancer. Indeed, this approach has recently been used to improve the 
prediction of outcome in patients who underwent potentially curative resection for 
colorectal cancer (Canna et al, 2005).
An elevated circulating C-reactive protein concentration is also an established 
poor prognostic factor in patients with metastatic renal cancer (Atzpodien et al., 2003; 
Bromwich et al., 2004; Casamassima et ai., 2005). In our previous study of patients 
with metastatic renal cancer (Bromwich et al., 2004) approximately 70% had an 
elevated C-reactive protein (>10mg/l) compared with approximately 40% in the present 
study of primary operable disease. This is consistent with previous observations that 
the systemic inflammatory response increases with advancing disease (Mahmoud and 
Rivera, 2002). However, the basis of the independent relationship between an elevated 
C-reactive protein concentration and poor survival in renal cancer is not clear. There 
are a number of possible explanations. Firstly, that an elevated C-reactive protein 
identifies tumours capable of producing significant amounts of pro-inflammatory 
cytokines, in particular interleukin-6 (Kinoshita et al., 1999; McKeown et al., 2004) and 
therefore with the potential for more rapid growth of tumour cells (Jee et al., 2001; 
Trika et al., 2003). Also, that an elevated C-reactive protein identifies those patients 
with T-lymphocyte impaiiment (Maccio et al., 1998; Canna et a l, 2005) or patients with
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a pro-angiogenic environment (Kofler et al., 2005; Xavier et al., 2006) allowing 
unrestrained tumour growth and dissemination. Clearly, both these tumour and host 
mechanisms may be related and required for the greater malignant potential associated 
with an elevated C-reactive protein concentration.
This is a relatively small, partially retrospective study and requires verification in 
larger prospective cohorts. However, if an elevated C-reactive protein concentration is 
shown to offer prognostic value in addition to the crurent UISS criteria it would 
improve oiu staging of these patients. Moreover, C-reactive protein may offer a useful 
pre-operative therapeutic target in patients imdergoing potentially curative surgery for 
renal clear cell cancer.
In summary, the presence of a pre-operative systemic inflammatory response 
predicts poor cancer specific survival in patients who have undergone potentially 
curative resection for renal clear' cell cancer.
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Table 2.1 Clinicopathological characteristics in patients undergoing potentially 
curative resection for renal cancer.
Patients
(n= 100)
Age group (<60/ >60 yrs) 43/ 57
Sex (male/ female) 59/41
T stage (1/2/ 3/4) 36/19/ 42/3
Fuhiman grade (1/11/ III/ IV) 18/39/26/ 13
ECOG-ps (0 /> l) 86/14
UISS (low/ intermediate/ high) 22/ 69/9
C-reactive protein (<10/ >10mg/l) 58/42
Alive/ dead 75/25
Cancer specific/ intercurrent disease 18/7
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Table 2.2 The relationship between the presence of a pre-operative systemic 
inflammatory response and clinicopathological characteristics of renal clear cell
cancer.
Age group (<60/ >60 yrs) 
Sex (male/ female) 
Tumour stage (1/ 2/ 3/ 4) 
Fuhrman grade 
(1/ II/ III/IV)
ECOG-ps (0/> l)
UISS
(low/ intermediate/ high)
C-reactive protein C-reactive protein p-value
< lOmg/1 (n= 58) > lOmg/1 (n = 42)
26/32 17/25 0.664
36/22 23/ 19 0.463
28/ 12/ 18/0 8 /7 /24 /3  0.003
10/28/ 14/3 8/ 11/12/ 10 0.021
54/4 
17/ 40/1
32/10 
5/ 29/8
0.016
0.003
Cancer specific 
Survival (months)*
*Mean (95%CI)
95.9 (89.8-102.0) 70.8 (57.8-83.8) <0.001
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Figure 2.1. Relationship between preoperative C-reactive protein (<10/ >10mg/l 
from top to bottom) and cancer-specific survival in “low or intermediate risk” 
patients (n= 91) undergoing potentially curative resection for renal cancer.
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Chapter 3
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3 THE RELATIONSHIP BETWEEN THE SYSTEMIC INFLAMMATORY
RESPONSE, TUMOUR T-LYMPHOCYTE INFILTRATION, INTERLEUKIN-6 
RECEPTOR AND COX-2 EXPRESSION AND SURVIVAL IN PATIENTS 
UNDERGOING RESECTION FOR RENAL CANCER
3.1 Introduction
Renal cell cancer, although the most common cause of cancer death is one 
of the most lethal urological cancers. Each year in the UK, there are approximately 
3,500 new cases and approximately 30% of patients present with métastasés. Overall 
survival is poor; even in those who undergo potentially curative resection, only 
approximately half survive 5 years (Cancerstats, www. cancerresearchuk. o r .
It is increasingly recognised that cancer progression is dependent on a complex 
interaction of the tumour and host inflammatory response (O'Byrne and Dalgleish, 
2001; Coussens and Werb, 2002; Vakkila and Lotze, 2004). Recently, the systemic 
inflammatory response, as evidenced by elevated circulating concentrations of C- 
reactive protein, has been shown to be independently associated with poorer survival in 
patients with other advanced malignancies (O'Gorman et al., 2000; McMillan et al., 
2001; Maltoni et al., 2005). There is also evidence that C-reactive protein has 
independent prognostic value in a variety of primary operable cancers (McMillan et ah, 
2003; Ikeda et al., 2003; Hilmy et al., 2005; Jamieson et al., 2005). It would appear that 
the systemic inflammatory response is of considerable importance in the relationship 
between the tumour, the host and outcome in patients with cancer. Indeed, it has been 
reported that an elevated C-reactive protein is associated with poor cancer specific 
sui'vival in patients with operable renal cancer independent of tumoui' stage and grade 
(Masuda et ah, 1998; Chapter 2).
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The basis of the independent relationship between an elevated C-reactive protein 
concentration and poor survival in cancer is not clear. There are a number of possible 
explanations. Firstly, that an elevated C-reactive protein identifies tumours capable of 
producing significant amounts of pro-inflammatory cytokines, in particular inteiieukin- 
6 (Kinoshita et al., 1999; McKeown et al., 2004) and therefore with the potential for 
more rapid growth of tumour cells (Jee et al., 2001; Trikha et al., 2003) or to impair T- 
lymphocytic function (Maccio et al., 1998; Canna et al., 2005) allowing umestrained 
tumour growth and dissemination.
Precise localisation of pro-inflammatory cytokines to tumour cells or 
inflammatory cells within the tumour, particularly in paraffin embedded tissues, 
remains problematical (Canna et al., 2005) and the molecular basis of the increased 
production of interleukin-6 by the renal tumour remains to be defined. However, 
interleukin-6 activity has been assessed by staining for interleukin-6 receptor expression 
in a variety of solid tumours, including renal cancer (Costes et al., 1997) and infiltration 
of tumours with T- lymphocytes has been reliably demonstrated in a variety of solid 
tumours, including renal cancer (Nakano et al., 2001; Bromwich et al., 2003).
Central to the local inflammatory response is cyclooxygenase-2 and increased 
expression has been shown to be associated with poor survival in a number of common 
solid tumours (Dannenberg et al., 2001; Subbaramaiah and Dannenberg 2003). Cyclo­
oxygenase-2 is the rate limiting enzyme in the synthesis of prostaglandin E2 which is 
known to stimulate proliferation and inhibit apoptosis. Prostaglandin E2 is also 
recognised to induce interleukin-6 (Fosslien, 2000) and non-steroidal anti-inflammatory 
drugs have been shown to reduce interleukin-6 concentrations in cancer patients 
(McMillan et al., 1995; Shimizu et al., 2001) and animal cancer models (Cahlin et al., 
2000).
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In normal tissues cyclo-oxygenase-2 is usually absent, however, the kidney is 
unusual in that there is expression of cyclo-oxygenase-2 in health (Han'is, 2003). Few 
studies have examined the role of cyclo-oxygenase-2 in renal cancer. There is 
conflicting evidence as to whether increased cyclo-oxygenasse-2 expression is 
associated with poor survival in renal cancer (Miyata et al., 2003; Tuna et al., 2004).
The aim of the present study was therefore to examine the relationship between 
the systemic inflammatory response (C-reactive protein), interleukin-6 receptor 
expression, T-lymphocyte (CD4+, CD8+) infiltration and cyclo-oxygenase-2 expression 
and cancer specific survival in patients with renal cell carcinoma.
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3.2 Patients and Methods
Patients diagnosed with renal clear cell cancer, who underwent resection 
between November 1997 and April 2004 in the West of Scotland, were included in the 
study.
Patients were staged clinically on the basis of surgical findings and pre-operative 
computed tomography of chest abdomen and pelvis and pathologically according to the 
1997 UICC TNM classification of renal tumours (Sobin et ah, 1997). Tumours were 
graded by experienced pathologists according to criteria set out by Fuhrman and 
coworkers (1982). Also, routine laboratory measurement of C-reactive protein was 
carried out.
The Research Ethics Committee of North Glasgow NHS Trust approved the
study.
3.2.1 C-Reactive Protein
Routine laboratory measurement of patient's serum for C-reactive protein 
concentration was performed. The limit of detection of the assay was a C-reactive 
protein concentration lower than 6mg/l. The coefficient of variation, over the range of 
measurement, was less than 5% as established by routine quality control procedures. C- 
reactive protein measurement of greater than lOmg/1 was considered to indicate the 
presence of systemic inflammatory response (O'Gorman et al., 2000; Ramsey et al., 
2005).
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3.2.2 Immunohistochemistrv
Blocks from the primary tumom* were fixed in 10% buffered formalin and 
embedded in paraffin wax. One representative block of tumour was selected for each 
patient. Sections (4 mm) were cut and mounted on slides coated with 
aminopropyltriethoxysilane. Slides were dewaxed in xylene and rehydrated using 
graded alcohols 100, 90 and 70% and water. Slides were then immersed in 0.3% 
hydrogen peroxide for 10 minutes (20 minutes for cyclo-oxygenase-2 and interleukin-6 
receptor) to block endogenous peroxidases.
The following monoclonal antibodies were used; CD4 mouse monoclonal 
(Vector, Peterborough, UK) antibody 1:50 dilution. CD8 mouse monoclonal (Dako, 
Cambridgeshire, UK) antibody 1:100. Cyclo-oxygenase-2 IgG (Cayman Chemical Co., 
MI, USA) antibody 1:800 dilution. InterIeukin-6 receptor a  rabbit polyclonal (Santa 
Cmz Biotechnology Inc, USA) 1:500.
Antigen retrieval for CD4+ and interleukin-6 receptor was carried out by 
incubating in lOmM citrate buffer (Epitope retrieval solution x 10, Dako) in a calibrated 
water bath at 96°C for 75 minutes and 20 minutes respectively. Antigen retrieval for 
CD8+ and cyclo-oxygenase-2 was canred out by microwaving in 1 mM Tris EDTA 
buffer (5mM Tris base pH 8.0 and ImM Sodium EDTA) for 5 minutes under full 
pressure in a plastic pressure cooker in a 85OW microwave on full power.
Non specific background staining was blocked using 1.5%. v/v normal horse 
serum in tri-phosphate buffered saline (TBS) and incubated for 15 minutes at room 
temperature. Only cyclo-oxygenase-2 underwent further block with avidin-biotin 
horseradish peroxidase complex solution (Vector Labs Inc., CA, USA) as per 
manufacturer’s instructions. Sections were then blotted and incubated with CD4+ or
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CD8+ or cyclo-oxygenase-2 or interleukin-6 receptor primary antibody at the above 
dilutions for 30 minutes at 27°C in a temperature controlled moisture chamber (chamber 
and same temperature used for all antibody incubations). CD4+ and CD8+ sections 
were then immunostained using the peroxidase-based Envision (Dako, Cambridgeshire, 
UK) technique Figui'es 3.1 and 3.2. Cyclo-oxygenase-2 and interleukin-6 receptor 
sections were immunostained using avidin-biotin based Lsab Plus kit (Dako, 
Cambridgeshire, UK) Figui’es 3.3 and 3.4. Sections were counterstained with 
haematoxylin, dehydrated, cleared and mounted with Pertex.
3.2.3 Mornhometrv
Quantitative analysis of the lymphoid infiltrate was performed using point 
counting with a random sampling technique as previously described (Bromwich et al, 
2003). With this method, the volume occupied by any given component (volume 
density) is expressed as a percentage of the total volume of the tissue. In the present 
study, the volumes of CD4+ and CD8+ immunopositive cells were calculated as 
percentage of the total tumour volume. A 100 point ocular grid was used at x 400 
magnification and 30 fields were counted per case for each antibody. Fields were 
scored according to the number of positively stained cells lying in contact with the 
vertical and horizontal cross hatch of the hundred point grid. Only fields within the 
tumour (including cancer cell nests and surrounding tissue stroma) were counted. Any 
normal tissue on the slide was excluded from the analysis. This final method was 
designed on the basis of a pilot study, which demonstrated that the volume density of 
CD4+ and CD8+ of two observers reached a plateau after 25-30 fields. This pilot study 
also demonstrated that CD4+ and CD8+ counts were equivalent to the CD3+ counts 
(unpublished data). The observers were blinded to the clinical outcome of the patient.
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Cyclo-oxygenase-2 and interlenkin-6 receptor expression were assessed as 
previously described (Wendrum et al., 2003). Percentage tumour cells stained were 
scored as 0-20% = 1, 21-50% -  2 and 51-100% = 3. This score is then multiplied by 
the predominant intensity of staining; 0 = no stain, 1 = weak stain, 2 = moderate stain 
and 3 = strong staining gaining a final score ranging from 0 - 9 .  For analysis, scores 
were grouped in tertiles.
Slides were examined by independent observers (GWAL, SR and PAM) blind to 
the clinical outcome of each patient.
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Figure 3.1 Immunohistochemical staining of CD4+ T-lymphocytes (brown)
within clear cell carcinoma of kidney (blue).
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Figure 3.2 Immunohistochemical staining of CD8+ T-lymphocytes (brown) 
within clear cell carcinoma of kidney (blue)
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Figure 3.3 Immunohistochemical staining of cyclo-oxygenase-2 (brown) within
renal clear cell cancer (blue).
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Figure 3.4 Immunohistochemical staining of interleukin-6 receptor (brown) 
within renal clear cell carcinoma (blue).
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3.2,4 Statistics
Compaiisons between groups of patients were carried out using contingency 
table analysis (X^) for trend as appropriate. Survival analysis was performed using the 
Cox’s proportional-hazards model. Deaths up to the end of February 2006 were 
included in the analysis. Multivariate sui’vival analysis was performed using a stepwise 
backward procedure to derive a final model of the variables that had a significant 
independent relationship with survival. To remove a variable from the model, the 
corresponding P-value had to be greater than 0.10. Analysis was performed using SPSS 
software (SPSS Inc., Chicago, IL, USA).
3,3 Results
The characteristics and cancer specific sur vival of patients with renal cancer who 
underwent resection (n= 72) are shown in Table 3.1 and Appendix II. The majority of 
patients were male and similar numbers had localised or advanced disease. 
Immunohistochemical scores were grouped in tertiles for analysis. Approximately 40% 
had an elevated C-reactive protein concentration (>10mg/l).
The minimum follow-up was 23 months; the median follow-up of the survivors 
was 62 months. During this period 22 patients died; 16 patients of their cancer and 6 of 
intercun’ent disease. On univariate sui’vival analysis, age (p<0.05), tumour stage 
(p<0.01), Fuhiman grade (p<0.001), tumour CD4+ T-lymphocytic infiltration (p<0.05), 
tumoui’ cyclo-oxygenase-2 expression (p<0.10) and C-reactive protein (p<0.01) were 
significant predictors of cancer specific survival. On multivariate analysis with age, 
tumour stage, grade, tumour CD4+ T-lymphocytic infiltration, cyclo-oxygenase-2 
expression and C-reactive protein entered as covariates, tumour stage (HR 7.73, 95%CI 
1.63-36.62, p-0.010), grade (HR 3.08, 95%CI 1.60-5.94, p<0.001) and C-reactive
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protein (HR 2.78, 95% Cl 1.00-8.84, p=0.046) were independent predictors of cancer 
specific survival.
Patients grouped according to stage are shown in Table 3.2. The groups were 
similar in terms of age, sex, tumour T-lymphocytic infiltration, cyclo-oxygenase-2 
expression and interleukin-6 receptor expression. An increased tumour stage was 
associated with an increase in grade (p<0.05), and C-reactive protein (p<0.05).
The inter-relationships between the clinicopathological characteristics in patients 
undergoing resection for renal cancer aie shown in Table 3.3. An increase in tumour 
CD4+ T-lymphocytic infiltration was associated with increased Fuhrman grade 
(p<0.01) and CD8+ T-lymphocytic infiltration (p<0.001). An increase in tumour CD8+ 
T-lymphocytic infiltration was associated with an increase in cyclo-oxygenase-2 
expression (p<0.05). An increase in interleukin-6 receptor expression was associated 
with an elevated C-reactive protein (p<0.10). An elevated C-reactive protein was 
associated with increased tumour grade (p<0.01).
There was a significant direct relationship between C-reactive protein and 
percentage tumour CD4+ T-lymphocytes (is=0.34, p=0.003) and CD8+ T-lymphocytes 
(rs-0.29, p=0.014).
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3.4 Discussion
In the present study the presence of both local (tumour CD4+ lymphocytic 
infiltrate, cyclo-oxygenase-2 expression) and systemic (C-reactive protein) 
inflammatory responses were associated with poor cancer specific survival in patients 
undergoing resection for renal cancer. However, only C-reactive protein had 
independent prognostic value.
The relationship between increased tumour CD4+ lymphocytic infiltrate and 
poor cancer-specific survival is the opposite of that previously reported in patients with 
primary operable colorectal cancer (Canna et al., 2005). Furthermore, Canna and 
coworkers (2005) reported that increased tumoui- CD4+ lymphocytic infiltrate was 
inversely, rather than directly, associated with C-reactive protein. Nevertheless, 
consistent with our data, C-reactive protein had independent prognostic value whereas 
tumour CD4+ lymphocytic infiltrate did not (Canna et al., 2005).
The reasons for the contrasting relationships between tumour CD4+ lymphocytic 
infiltrate and C-reactive protein in these different tumours is not clear. However, it is 
well recognised that, in contrast to colorectal cancer, renal cancer is strongly 
immunogenic (Zou, 2005). In the present study, tumour CD4+ lymphocytic infiltrate 
was strongly associated with tumour grade and would be consistent with the tumour 
CD4+ lymphocytic infiltrate being directly linked to the malignant potential of the 
tumour.
There was a direct correlation between CD8+ lymphocytic infiltrate and cyclo- 
oxygense-2 expression in renal cancer patients. This is in contrast with observations in 
endometrial cancer where an inverse relationship has been observed (Ohno et al., 2005). 
Ohno and co workers suggest that in endometrial cancer cyclo-oxygenase-2 produced
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by tumour cells reduces CD8+ infiltration and subsequently confers a poorer prognosis. 
Neither CD8+ lymphocytic infiltrate or cyclo-oxygenase-2 expression were 
independently prognostic in renal cancer and although significantly associated this 
would not appear to be an important step in tumour progression.
Elevated circulating C-reactive protein concentrations are primarily determined by 
circulating interleukin-6 (Gabay and Kusliner, 1999). Interleukin-6 is expressed in the 
majority of renal cancers and has been proposed as an autocrine growth factor (Takenawa 
et aL, 1991; Blay et al 1992; Paule et al., 2000). Furthermore, circulating inteiieukin-6 is 
associated with increased tumour grade, volume and metastasis in patients with renal 
cancer (Yoshida et al., 2002). In ouf laboratory, previous groups have attempted to assess 
interleukin-6 within the paraffin embedded tumour samples using different methods of 
antigen retrieval and staining and the use of negative and positive controls. Co-workers in 
our laboratory have been unable to reliably identify regions of interleukin-6 expression 
due to deep background staining, which precludes accurate scoring of interleukin-6- 
positive cells in the tumour tissue (Canna et al., 2005). Interleukin-6 receptor expression 
is readily stained for and has been shown to correlate strongly with tumoui’ interleukin-6 
concentrations in a variety of solid tumours (Miki et al., 1989; Kinoshita et al., 1999). 
However, our results show tumour expression of interleukin-6 receptor not to be strongly 
associated with C-reactive protein. Further investigation of the relationship between 
tumour interleukin-6 immunohistochemical staining and circulating concentrations of C- 
reactive protein is warranted.
To our knowledge only one previous study has examined the prognostic value of 
tumour expression of interleukin-6 receptor (Costes et al., 1997). Costes and coworkers 
(1997) reported a significant association between the presence of the interleukin-6
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receptor in renal tumours and stage and grade. Furthermore, they reported that those 
patients with positive staining of interleukin-6 receptor had poorer survival. This is in 
contrast to our data where interleukin-6 receptor demonstrated no association with 
stage, grade or suiwival. This previous study examined 38 patients with mean follow-up 
14 months compared with 72 patients and a mean follow-up of approximately 5 years in 
the our cohort.
Few studies have examined the expression of cyclo-oxygenase-2 in renal cancer. 
Some studies have suggested that it is increased with tumour stage and grade (Miyata et 
ah, 2003, Hashimoto et al., 2003; Tuna et al., 2004). In contrast, other studies have 
shown no relationship (Cho et al., 2005). To date no studies have shown that tumour 
cyclo-oxygenase-2 expression has prognostic value (Miyata et a l, 2003; Tuna et a l, 
2004; Cho et a l, 2005). The basis of such differences in the relationship between 
tumoui’ cyclo-oxygenase-2 expression and tumour stage and grade in different studies is 
not clear. However, the lack of a relationship between tumour cyclo-oxygenase-2 
expression and tumour stage and grade in the present study and that of Cho and 
coworkers (2005) is consistent with tumour cyclo-oxygenase-2 expression having 
limited prognostic value. Additionally cyclo-oxygenase-2 expression was not 
associated with circulating C-reactive protein suggesting that in renal cancer the 
stimulating factors influencing the systemic inflammatory response are independent of 
local prostaglandin synthesis. This may be a consequence of the fact that cyclo- 
oxygenase-2 is expressed in normal renal endothelial tubular cells flom which tumour 
cells are thought to arise (Jones et a l, 1999).
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In suinmaiy, the results of the present study show that up-regulation of both 
local and systemic inflammatory responses are associated with poor cancer specific 
survival in patients undergoing resection for renal cancer. However, only the systemic 
inflammatoiy response (C-reactive protein) appears to have independent prognostic 
value.
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Table 3.1 Clinicopathological characteristics and survival in patients 
undergoing resection for renal cancer: univariate analysis.
Age group (<60/ >60 yrs) 
Sex (male/ female)
TNM stage (<11/>11)
Patients
(n=72)
35/37
43/29
37/35
Fuhrman grade (1/ II/ III/ IV) 16/ 29/ 14/12
T-lymphocytes
(% tumour volume)
CD4+ (tertiles 1,2,3)
CD8+ (tertiles 1,2,3)
Cy do -oxygenase-2
(tertiles 1,2,3) 
Interleukin-6 receptor 
(tertiles 1,2,3) 
C-reactive protein 
(<10/>10 mg/1)
0.45 (0.01-6.30)* 
0.90 (0.01-10.80)* 
100 (0-200)*
140 (0-300)*
Hazard ratio p-value
(95%CI)
0.20 (0.06-0.71) 0.013
0.67 (0.23-1.94) 0.463
10.27(2.33-45.35) 0.002
3.48 (1.94-6.24) <0.001
2.32(1.14-4.71) 0.020
1.39 (0.75-2.58) 0.296
1.73 (0.92-3.23) 0.088
0.95 (0.51-1.77) 0.878
40/32 5.20(1.67-16.20) 0.005
*median range
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Table 3.2 The relationship between tumour stage and clinicopathological 
characteristics in patients undergoing resection for renal cancer.
TNM stage <11 TNM stage >11 P-value
(n=37) (n=35)
Age group (<60/ >60 yrs) 15/ 22 20/15 0.162
Sex (male/ female) 21/16 22/13 0.600
Fuhrman grade (1/11/ III/ IV) 10/18/ 5/3 6 /11 /9 /9 0.017
T-lymphocytes
(% tumour volume)
CD4+ (tertiles 1,2,3) 12/16/9 12/ 8/15 0.390
CD8+ (tertiles 1,2,3) 11/14/11 12/10/13 0.774
Cyclo-oxygenase-2 14/14/ 9 10/10/15 0.152
(tertiles 1,2,3)
Interleukin-6 receptor 10/12/15 14/ 12/ 9 0.348
(tertiles 1,2,3)
C-reactive protein
(<10/>10 mg/1) 25/12 15/20 0.036
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4 DISCUSSION
4.1 Introduction
In Chapter 1 the aims of this thesis were defined as follows:
1. To examine the relationship between the pre-operative systemic inflammatory
response and cancer specific survival in patients undergoing potentially curative 
resection for renal clear cell cancer.
2. To examine the relationship between the systemic inflammatory response,
tumour T-lymphocyte infiltration, interleukin-6 receptor and COX-2 expression 
and survival in patients undergoing resection for renal cancer
4.2 General Discussion
Other than stage and grade there are few universally accepted criteria for 
predicting relapse in patients undergoing potentially curative resection for renal cancer. 
Patient factors are thought to be of importance and accordingly, in designing the UCLA 
Integrated Staging System (UISS), performance status was combined with stage and 
grade to give an overall risk of relapse (Zisman et a l, 2002).
The UISS has been developed from data accrued firom American surgical 
practice where traditionally a more aggressive approach is observed in the management 
of patients with potentially respectable disease. By definition, according to the criteria 
described in the original paper, patients defined as high risk of relapse have either T4 
disease indicating Invasion of gerotas fascia and surrounding structures or have locally 
advanced disease including renal vein involvement with a poor perfoimance status.
Considering patients with T4 disease which equates to TNM stage 4 disease only 
37% of patients will be alive after 1 year (Table 1.5). With regard to the locally 
advanced patients with poor performance status there is good evidence to suggest that
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more advance tumoiii's and poor performance status result in a significant increased risk 
of peri-operative mortality in a mainly elderly population of patients (Stephenson et ah, 
2004; Gupta et ah, 2004). These UISS high risk of relapse patients are less likely to be 
offered surgery on this basis in the U.K. This is reflected in our distribution of patients 
taken from a specialist centre for renal cancer where 22 were low, 69 intermediate and 
only 9 high risk patients. This is compared to the original paper which describes equal 
distribution of patients among the three categories (Zisman et ah, 2002). This makes 
the UISS potentially limited in application to a UK population as there is little 
stratification of UK patients undergoing nephi ectomy.
Previous work has suggested that the presence of a systemic inflammatory 
response is a stage independent negative prognostic factor in colorectal cancer 
(McMillan et ah, 2003), pancreatic cancer (Jamieson et ah, 2005) and urinary bladder 
cancer (Hilmy et ah, 2005). The study described in Chapter 2 shows that elevated 
circulating C-reactive protein is also an independent prognostic factor in patients 
undergoing potentially curative resection for renal cancer.
Elevated C-reactive protein as compared to ECOG-performance status is an 
objective variable with defined threshold and reproducible values (O’Gorman et ah, 
2000). Indeed studies incorporating both of these variables together have shown C- 
reactive protein to be of greater prognostic value on multivariate analysis (O’Gorman et 
ah, 2000; Bromwich et ah, 2003). This would suggest that compared to the somewhat 
more subjective performance status assessment versus the ease of measurement of C- 
reactive protein with greater numbers and longer follow up a more clinically useful 
prognostic score for a UK renal cancer population could be developed. This is further 
substantiated by the fact that within the large low and intermediate risk group described
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in chapter 2 we were able to demonstrate prognostic significance of elevated C-reactive 
protein in this sub-group analysis.
Further to this body of work myself and co-workers have pursued application 
and validation of the systemic inflammatory response into defining a Glasgow 
Prognostic Score (GPS) for renal cancer. The GPS was constructed as previously 
described by Forrest and co-workers (2003) in small cell lung cancer. Briefly, patients 
with both an elevated C-reactive protein (>10 mg/1) and hypoalbuminaemia (<35g/l) are 
allocated a score of 2. Patients in whom only one of these biochemical abnormalities is 
present were allocated a score of 1. Patients in which neither of these abnormalities are 
present ar e allocated a score of 0.
This was first published examining patients with metastatic renal cancer 
comparing the established Memorial Sloan Kettering Cancer Centre (MSKCC) and The 
Metastatic Renal Carcinoma Comprehensive Prognostic System (MRCCPS) scores with 
the GPS. The GPS predicts survival, independent of established scoring systems, in 
patients with metastatic renal cancer (Ramsey et al., 2007).
In a subsequent study C-reactive protein has been compared with other 
circulating systemic inflammatory markers namely neutrophil, lymphocyte, platelet and 
albumin concentration in conjunction with the validated Kattan, UCLA and Ssign score 
(Ramsey et al., 2007). C-reactive protein demonstrated superiority over all other 
systemic inflammatory markers in predicting outcome and stratification in patients 
undergoing curative nephrectomy for localized renal cancer. Indeed C-reactive protein 
alone proved superior to the Kattan score in predicting disease specific survival after 
nephrectomy. Within this study due to the independent superiority of C-reactive protein 
and tumour necrosis over albumin a refinement to the Glasgow Renal Cancer Prognostic 
Score should include both of these parameters. This represents the fulfillment of the
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pilot work carried out and described in chapter 2 of this thesis. Larger cohort studies 
with longer follow up as well as other institutions are required to internationally validate 
such a predictive score however the ease of application will potentially allow for greater 
uptake of its use in clinical practice.
Having examined the influence of the systemic inflammatory response on 
outcome in Chapter 3 we examined the relationship of the systemic and the local 
inflammatory response. To do this we looked at the local cellular mediators of the local 
inflammatory response defined by tumour lymphocytic infiltrate and the potential 
effector mediators of inflammation in the form of cyclo-oxygenase-2 and interleukin-6 
receptor.
The relationship between systemic and local inflammatory response has 
previously been reported in colorectal cancer where there was an inverse correlation 
between tumour CD4+ T-lymphocytic infiltration and circulating concentrations of C- 
reactive protein in patients undergoing resection (Canna et al., 2005).
By contrast we found a direct relationship between C-reactive protein and CD4+ 
lymphocytic infiltrate in patients with renal cancer. Renal cancer is a highly 
immunogenic tumour with the only proven treatment of advanced disease being 
immunotherapy (Bower et al., 1998).
It is of interest that despite a more pronounced CD4+ tumour lymphocytic 
infiltrate these patients have a worse outcome after sui'gery. This would suggest that 
despite being present in high numbers the T-lymphocytes are ineffective in mounting an 
appropriate response to either control development or prevent progression of the 
disease.
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It is perhaps less surprising that with such greater numbers of tumour 
inflammatory cells there is a direct correlation with C-reactive protein and the systemic 
inflammatory response. How these two factors are linked is not clear, but interleukin-6 
may be implicated as this cytokine has been previously suggested by Blay and co­
workers to act as an autocrine growth factor in renal cancer, and correlated well with 
serum C-reactive protein levels (1992). The site and source of production of 
interIeukin-6 is controversial. Either the tumour cells or the inflammatory infiltrate may 
excrete interleukin-6.
Accordingly we examined the local mediators of inflammation within renal 
cancer. Cyclo-oxygenase 2 is an important enzyme responsible for prostaglandin 
production and inflammation and has been implicated in the tumour genesis and 
progression of a number of solid tumours (Subbaramaiah and Dannenberg, 2003). 
Cyclo-oxygenase 2 produced prostaglandins are recognised to induce interleukin-6 
production (Fosslien, 2000)
As discussed in Chapter 3 direct staining of tissues for interleukin-6 itself has 
proven difficult by co-workers in our laboratory and accordingly staining for its receptor 
was used as a surrogate marker. Our study did not show any association between cyclo- 
oxygenase-2 expression and interleukin-6 receptor expression. Additionally, neither 
factor was an independent predictor of cancer specific survival. The lack of association 
would refute the hypothesis that tumour cyclo-oxygenase-2 expression and 
consequently local prostaglandin synthesis is responsible for local interleukin-6 
production in renal cancer. Both increased cyclo-oxygenase-2 expression and an 
increase in local interleukin-6 production in renal cancer were independent of the 
systemic inflammatory response. The limited prognostic value of cyclo-oxygenase-2
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and independence from the systemic inflammatory response may be related to renal 
tissue being unique in its constitutive expression of cyclo-oxygenase-2 in health.
Local prostaglandin cyclo-oxygenase-2 mediated inflammatory response would 
appear to be independent of the tumour CD4 lymphocytic infiltrate. Prostaglandins in 
renal cancer would therefore not seem to be important factors involved in recruitment of 
CD4+ lymphocytes previously shown to have independent prognostic significance.
Tumour cell expression of interleukin-6 receptor as a surrogate marker for 
interleukin-6 was independent of circulating C-reactive protein indicating that the 
interleukin-6 responsible for the systemic inflammatory response is produced by 
inflammatory supporting cells rather than the tumour itself. Indeed there was a positive 
relationship between CD4+ tumour lymphocytic infiltrate and C-reactive protein 
suggesting that these cells may be a potential soui'ce of interleukin-6.
This may offer an explanation as to why this infiltrate is ineffective in 
preventing tumoiu* progression in renal cancer. Th2 cells which are a subset of CD4h- 
T-lymphocytes, produce interleukin-6 as part of their cytokine profile promoting 
predominantly humoral immunity and a suppression of cytotoxic cellular response such 
as natural killer cells and CD8+ lymphocytes (Cher et al 1987; Stevens et al., 1988; 
Steiner et al., 1999). In comparison the Thl subset of CD4+ lymphocytes which 
produce both interleuikin-2 and interferons which have heen shown to improve survival 
in advanced cancer and promote a cytotoxic cell mediated immunity (Bower et al., 
1998). Therefore, it may be that a predominance of the Th2 subset in those patients 
with greater T-lymphocytic infiltrate would explain the poorer cancer specific survival.
Further work has demonstrated that patients with an elevated systemic 
inflammatory response pre-operatively ti'eated with nephrectomy show little in the way
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of normalisation of C-reactive protein, serum interleukin-6 and serum interleukin-10 at 
3 months post procediue (Ramsey et al. 2006). Fujikawa and co-workers (1999) 
examining C-reactive protein in patients undergoing cytoreductive nephrectomy 
propose that patients with an elevated postoperative nadir C-reactive protein may 
signify interleukin-6 secretion at a higher rate from metastatic lesions. The more 
probable explanation based on the work published in this thesis and subsequent study by 
Ramsey and co-workers (2006) would suggest that this persistently elevated systemic 
inflammatory response is unlikely to be determined by the tumour or the metastatic 
lesions but rather an impaired immune cytokine response in patients with renal cancer.
The assertion that the source of interleukin-6 and interleuikin-10 is out with the 
tumoui- itself is supported by this thesis. Interleukin-6 receptor expression was not 
significantly associated with systemic C-reactive protein. Preliminary unpublished 
work by myself and co-workers has failed to show any direct link between tissue 
interleukin-6 receptor expression and elevated serum interleukin-6 concentrations in a 
small number of patients studied. A biological model of a patient with impaired 
cytokine mediated immune response facilitating tumour development and progression 
could be explained on the basis of these results. To expand this theory the tissue micro­
environment is based on a systemic decline rather than anything local to the tumour 
itself and as such a systemic therapy is required to address the poor prognosis of 
patients with evidenced elevated systemic inflammatory response.
As mentioned earlier in this discussion the possibility of the local infiltrate 
CD4+ lymphocytic helper subset determining the extent and the effect of the CD8+ 
lymphocytic infiltrate may be suggested by the correlation between CD4+ lymphocytic 
infiltrate and systemic C-reactive protein. In light of the study by Ramsey and co­
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workers (2006) which suggests the source of the inflammatory cytokines to be separate 
from the tumour this would appear an inadequate explanation.
One hypothesis based on the work in this thesis would be that the tumour 
lymphocytic infiltrate is a local representation of the immune system as a whole. 
Furthermore a generic alteration in the cytokine profile of active CD4+ lymphocytes 
throughout the body is skewed towards the Th2 subset hence fitting the biological 
model of a patient with impaired cytokine mediated immune response facilitating 
tumour development and progression. Ramsey and co-workers (2006) demonstrated a 
positive significant association between the hallmark cytokines of Th2 CD4+ 
lymphocytes, systemic interleuikin-6 and interleukin-10 in patient with renal cancer. 
Further work is warranted to study these serological markers of eytokine expression 
along with the tissue based lymphocytic infiltrate.
The growing body of evidence including the work presented in this thesis 
suggest that both the local and systemic inflammatory response are of significant 
importance in determining survival in patients with renal cancer. Interleukin-6 remains 
the most probable inflammatory mediator to link the inflammatory processes and 
although OUI* data may speculatively propose that the inflammatory cells and an 
impaired immune system aie responsible, the site and source of production remain 
unclear and fuither study is warranted.
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5 CONCLUSIONS
The outcome of this work would suggest that the presence of a systemic 
inflammatory response is a negative prognostic factor. Measurement of C-reactive 
protein and the association with outcome in renal cancer would appear to be of 
significant importance. CuiTently the West Of Scotland Renal Cancer Database 
continues to collect prospective data including C-reactive protein on patients 
undergoing nephrectomy for renal cancer. With increasing patient numbers and follow 
up of these additional patients and those reported in this thesis the primary objective of 
this data would be the further development of the Glasgow Prognostic Score algorithm.
The systemic response was directly related to an increased T-lymphocytic 
infiltrate. Why this lymphocytic infiltrate is ineffective in preventing tumour 
progression is unclear, but on the basis of this research it would appear to be 
independent of cyclo-oxygenase-2 mediated local interleukin-6 production.
Further work is required to define the possible mechanisms by which the local 
inflammatory infiltrate has a negative effect on outcome in renal cancer whereas it has 
survival benefit in other tumours. Interleukin-6 is a cytokine associated with a CD4+ 
type 2 humoral immunity and suppresses the cytotoxic immune response. Another 
important inhibitory cytokine is interleukin-10 known to attenuate immune function and 
produced by the same CD4+ type 2 lymphocytic subset. It would be of interest to 
examine how serum and tissue levels of interleukin-10 relate to circulating C-reactive 
protein and tumoui' lymphocytic infiltrate in renal cancer.
In conclusion the present studies would suggest the systemic inflammatory 
response may be a useful therapeutic target in patients with primary renal clear cell 
carcinoma.
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